How to ask about, and manage, the undertreated problem of sexual dysfunction

Article Type
Changed
Tue, 08/28/2018 - 11:02
Display Headline
How to ask about, and manage, the undertreated problem of sexual dysfunction

Author and Disclosure Information

Barbara S. Levy, MD

Dr. Levy is Vice President for Health Policy at the American College of Obstetricians and Gynecologists in Washington, DC. She serves on the OBG Management Board of Editors.

Audio / Podcast
Issue
OBG Management - 24(09)
Publications
Topics
Sections
Audio / Podcast
Audio / Podcast
Author and Disclosure Information

Barbara S. Levy, MD

Dr. Levy is Vice President for Health Policy at the American College of Obstetricians and Gynecologists in Washington, DC. She serves on the OBG Management Board of Editors.

Author and Disclosure Information

Barbara S. Levy, MD

Dr. Levy is Vice President for Health Policy at the American College of Obstetricians and Gynecologists in Washington, DC. She serves on the OBG Management Board of Editors.

Issue
OBG Management - 24(09)
Issue
OBG Management - 24(09)
Publications
Publications
Topics
Article Type
Display Headline
How to ask about, and manage, the undertreated problem of sexual dysfunction
Display Headline
How to ask about, and manage, the undertreated problem of sexual dysfunction
Sections
Article Source

PURLs Copyright

Inside the Article

Is elective delivery at 37 weeks’ gestation safe in uncomplicated twin pregnancies?

Article Type
Changed
Tue, 08/28/2018 - 11:00
Display Headline
Is elective delivery at 37 weeks’ gestation safe in uncomplicated twin pregnancies?

In uncomplicated twin pregnancies, timing of delivery remains an area of controversy. The optimal length of gestation appears to be shorter in twins, compared with singleton pregnancies. Although population-based studies are limited by the inclusion of complicated pregnancies, data suggest that the nadir in perinatal mortality occurs at 37 to 39 weeks in twins versus 39 to 41 weeks in singletons.1 It is reasonable, therefore, to consider elective delivery of uncomplicated twin pregnancies prior to 39 weeks’ gestation, when elective delivery of singleton pregnancies becomes an option. The American College of Obstetricians and Gynecologists suggests that it is safe to continue uncomplicated twin pregnancies beyond 37 weeks, although there is a lack of prospective data to establish the optimal time of delivery.

Details of the study

Enter Dodd and colleagues, who conducted their randomized, controlled trial to assess the risks and benefits of elective delivery of twins at 37 weeks. In this multicenter study from Australia, women who had uncomplicated twin pregnancies at 36 6/7 weeks or beyond with no contraindication to continuing the pregnancy were randomly assigned to:

  • an elective birth group, with planned delivery at 37 weeks, or
  • a “standard care” group, with delivery planned at 38 weeks or later.

The primary outcome was a composite of serious adverse outcome for the infants, including death and serious morbidity.

The elective birth group delivered at a mean (SD) gestational age of 37.3 (0.4) weeks, versus 37.9 (0.5) weeks for the standard care group. In both groups, more than 80% of pregnancies were dichorionic, and elective cesarean delivery was performed in approximately one-third of women.

Although the primary outcome was less common in the elective birth group, the difference was due entirely to a higher rate of birthweight below the third centile (for gestational age at birth and infant sex) in the standard care group, with no difference in any other individual outcome. The only neonatal death occurred 27 days after birth as a result of group B streptococcus sepsis in one newborn from the standard care group. Induction of labor occurred more frequently in the elective birth group than in the standard care group (50.9% vs 37.8%; P = .046).

Strengths and weaknesses of the trial

Among the strengths of this study is the fact that it is the largest published randomized, controlled trial addressing the timing of delivery in uncomplicated twin pregnancies. It also appears to have been well conducted and appropriately analyzed.

The main weakness is that nearly all primary outcomes in both groups involved birthweights below the 3rd centile rather than mortality or clinical outcomes associated with significant morbidity in the newborn period.

No information on ultrasonographic monitoring of fetal growth was provided; it is possible that more aggressive screening could have identified growth restriction, rendering some patients ineligible for randomization and ultimate inclusion in the trial. In addition, nearly 20% of pregnancies were monochorionic; these gestations are typically delivered at early gestational ages due to higher rates of intrauterine mortality.2

WHAT THIS EVIDENCE MEANS FOR PRACTICE

This study provides reassurance that elective delivery at 37 weeks is likely to be safe and could reduce the rate of intrauterine growth restriction. Achieving this reduction would require a higher rate of induction of labor in this population.

An important consideration is the association between elective cesarean delivery and neonatal respiratory disorders, which has been noted in twins3 as well as in singletons.4 Therefore, unless there is an indication for earlier delivery, it may be reasonable to await scheduled cesarean delivery at 38 weeks.

Because of a higher rate of intrauterine mortality among monochorionic twins, it is prudent to deliver these pregnancies by 37 weeks.

Stephen T. Chasen, MD

We want to hear from you! Tell us what you think.

References

1. Kahn B, Lumey LH, Zybert PA, et al. Prospective risk of fetal death in singleton, twin, and triplet gestations: implications for practice. Obstet Gynecol. 2003;102(4):685-692.

2. Breathnach FM, McAuliff FM, Geary M, et al. Perinatal Ireland Research Consortium. Optimum timing for planned delivery of uncomplicated monochorionic and dichorionic twin pregnancies. Obstet Gynecol. 2012;119(1):50-59.

3. Chasen ST, Madden A, Chervenak FA. Cesarean delivery of twins and neonatal respiratory disorders. Am J Obstet Gynecol. 1999;181(5 pt 1):1052-1056.

4. Tita AT, Landon MB, Spong CY, et al. Eunice Kennedy Shriver NICHD Maternal-Fetal Medicine Units Network. Timing of elective repeat cesarean delivery at term and neonatal outcomes. N Engl J Med. 2009;360(2):111-120.

Article PDF
Author and Disclosure Information

EXPERT COMMENTARY

Stephen T. Chasen, MD
Director of High-Risk Obstetrics and Director of Maternal-Fetal Medicine Fellowship, New York Weill Cornell Medical Center, and Associate Professor of Obstetrics and Gynecology, Weill Cornell Medical College, New York City.

Issue
OBG Management - 24(09)
Publications
Topics
Page Number
56-55
Legacy Keywords
Stephen T. Chasen MD;elective delivery;gestation;uncomplicated twin pregnancy;expectant management;37 weeks;timing of delivery;length of gestation;neonatal respiratory disorders;perinatal mortality;singleton;ACOG;dichorionic;monochorionic;elective cesarean delivery;birthweight;neonatal death;group B streptococcus;sepsis;ultrasonography;fetal growth;growth restriction;Examining the Evidence;induction of labor;
Sections
Author and Disclosure Information

EXPERT COMMENTARY

Stephen T. Chasen, MD
Director of High-Risk Obstetrics and Director of Maternal-Fetal Medicine Fellowship, New York Weill Cornell Medical Center, and Associate Professor of Obstetrics and Gynecology, Weill Cornell Medical College, New York City.

Author and Disclosure Information

EXPERT COMMENTARY

Stephen T. Chasen, MD
Director of High-Risk Obstetrics and Director of Maternal-Fetal Medicine Fellowship, New York Weill Cornell Medical Center, and Associate Professor of Obstetrics and Gynecology, Weill Cornell Medical College, New York City.

Article PDF
Article PDF

In uncomplicated twin pregnancies, timing of delivery remains an area of controversy. The optimal length of gestation appears to be shorter in twins, compared with singleton pregnancies. Although population-based studies are limited by the inclusion of complicated pregnancies, data suggest that the nadir in perinatal mortality occurs at 37 to 39 weeks in twins versus 39 to 41 weeks in singletons.1 It is reasonable, therefore, to consider elective delivery of uncomplicated twin pregnancies prior to 39 weeks’ gestation, when elective delivery of singleton pregnancies becomes an option. The American College of Obstetricians and Gynecologists suggests that it is safe to continue uncomplicated twin pregnancies beyond 37 weeks, although there is a lack of prospective data to establish the optimal time of delivery.

Details of the study

Enter Dodd and colleagues, who conducted their randomized, controlled trial to assess the risks and benefits of elective delivery of twins at 37 weeks. In this multicenter study from Australia, women who had uncomplicated twin pregnancies at 36 6/7 weeks or beyond with no contraindication to continuing the pregnancy were randomly assigned to:

  • an elective birth group, with planned delivery at 37 weeks, or
  • a “standard care” group, with delivery planned at 38 weeks or later.

The primary outcome was a composite of serious adverse outcome for the infants, including death and serious morbidity.

The elective birth group delivered at a mean (SD) gestational age of 37.3 (0.4) weeks, versus 37.9 (0.5) weeks for the standard care group. In both groups, more than 80% of pregnancies were dichorionic, and elective cesarean delivery was performed in approximately one-third of women.

Although the primary outcome was less common in the elective birth group, the difference was due entirely to a higher rate of birthweight below the third centile (for gestational age at birth and infant sex) in the standard care group, with no difference in any other individual outcome. The only neonatal death occurred 27 days after birth as a result of group B streptococcus sepsis in one newborn from the standard care group. Induction of labor occurred more frequently in the elective birth group than in the standard care group (50.9% vs 37.8%; P = .046).

Strengths and weaknesses of the trial

Among the strengths of this study is the fact that it is the largest published randomized, controlled trial addressing the timing of delivery in uncomplicated twin pregnancies. It also appears to have been well conducted and appropriately analyzed.

The main weakness is that nearly all primary outcomes in both groups involved birthweights below the 3rd centile rather than mortality or clinical outcomes associated with significant morbidity in the newborn period.

No information on ultrasonographic monitoring of fetal growth was provided; it is possible that more aggressive screening could have identified growth restriction, rendering some patients ineligible for randomization and ultimate inclusion in the trial. In addition, nearly 20% of pregnancies were monochorionic; these gestations are typically delivered at early gestational ages due to higher rates of intrauterine mortality.2

WHAT THIS EVIDENCE MEANS FOR PRACTICE

This study provides reassurance that elective delivery at 37 weeks is likely to be safe and could reduce the rate of intrauterine growth restriction. Achieving this reduction would require a higher rate of induction of labor in this population.

An important consideration is the association between elective cesarean delivery and neonatal respiratory disorders, which has been noted in twins3 as well as in singletons.4 Therefore, unless there is an indication for earlier delivery, it may be reasonable to await scheduled cesarean delivery at 38 weeks.

Because of a higher rate of intrauterine mortality among monochorionic twins, it is prudent to deliver these pregnancies by 37 weeks.

Stephen T. Chasen, MD

We want to hear from you! Tell us what you think.

In uncomplicated twin pregnancies, timing of delivery remains an area of controversy. The optimal length of gestation appears to be shorter in twins, compared with singleton pregnancies. Although population-based studies are limited by the inclusion of complicated pregnancies, data suggest that the nadir in perinatal mortality occurs at 37 to 39 weeks in twins versus 39 to 41 weeks in singletons.1 It is reasonable, therefore, to consider elective delivery of uncomplicated twin pregnancies prior to 39 weeks’ gestation, when elective delivery of singleton pregnancies becomes an option. The American College of Obstetricians and Gynecologists suggests that it is safe to continue uncomplicated twin pregnancies beyond 37 weeks, although there is a lack of prospective data to establish the optimal time of delivery.

Details of the study

Enter Dodd and colleagues, who conducted their randomized, controlled trial to assess the risks and benefits of elective delivery of twins at 37 weeks. In this multicenter study from Australia, women who had uncomplicated twin pregnancies at 36 6/7 weeks or beyond with no contraindication to continuing the pregnancy were randomly assigned to:

  • an elective birth group, with planned delivery at 37 weeks, or
  • a “standard care” group, with delivery planned at 38 weeks or later.

The primary outcome was a composite of serious adverse outcome for the infants, including death and serious morbidity.

The elective birth group delivered at a mean (SD) gestational age of 37.3 (0.4) weeks, versus 37.9 (0.5) weeks for the standard care group. In both groups, more than 80% of pregnancies were dichorionic, and elective cesarean delivery was performed in approximately one-third of women.

Although the primary outcome was less common in the elective birth group, the difference was due entirely to a higher rate of birthweight below the third centile (for gestational age at birth and infant sex) in the standard care group, with no difference in any other individual outcome. The only neonatal death occurred 27 days after birth as a result of group B streptococcus sepsis in one newborn from the standard care group. Induction of labor occurred more frequently in the elective birth group than in the standard care group (50.9% vs 37.8%; P = .046).

Strengths and weaknesses of the trial

Among the strengths of this study is the fact that it is the largest published randomized, controlled trial addressing the timing of delivery in uncomplicated twin pregnancies. It also appears to have been well conducted and appropriately analyzed.

The main weakness is that nearly all primary outcomes in both groups involved birthweights below the 3rd centile rather than mortality or clinical outcomes associated with significant morbidity in the newborn period.

No information on ultrasonographic monitoring of fetal growth was provided; it is possible that more aggressive screening could have identified growth restriction, rendering some patients ineligible for randomization and ultimate inclusion in the trial. In addition, nearly 20% of pregnancies were monochorionic; these gestations are typically delivered at early gestational ages due to higher rates of intrauterine mortality.2

WHAT THIS EVIDENCE MEANS FOR PRACTICE

This study provides reassurance that elective delivery at 37 weeks is likely to be safe and could reduce the rate of intrauterine growth restriction. Achieving this reduction would require a higher rate of induction of labor in this population.

An important consideration is the association between elective cesarean delivery and neonatal respiratory disorders, which has been noted in twins3 as well as in singletons.4 Therefore, unless there is an indication for earlier delivery, it may be reasonable to await scheduled cesarean delivery at 38 weeks.

Because of a higher rate of intrauterine mortality among monochorionic twins, it is prudent to deliver these pregnancies by 37 weeks.

Stephen T. Chasen, MD

We want to hear from you! Tell us what you think.

References

1. Kahn B, Lumey LH, Zybert PA, et al. Prospective risk of fetal death in singleton, twin, and triplet gestations: implications for practice. Obstet Gynecol. 2003;102(4):685-692.

2. Breathnach FM, McAuliff FM, Geary M, et al. Perinatal Ireland Research Consortium. Optimum timing for planned delivery of uncomplicated monochorionic and dichorionic twin pregnancies. Obstet Gynecol. 2012;119(1):50-59.

3. Chasen ST, Madden A, Chervenak FA. Cesarean delivery of twins and neonatal respiratory disorders. Am J Obstet Gynecol. 1999;181(5 pt 1):1052-1056.

4. Tita AT, Landon MB, Spong CY, et al. Eunice Kennedy Shriver NICHD Maternal-Fetal Medicine Units Network. Timing of elective repeat cesarean delivery at term and neonatal outcomes. N Engl J Med. 2009;360(2):111-120.

References

1. Kahn B, Lumey LH, Zybert PA, et al. Prospective risk of fetal death in singleton, twin, and triplet gestations: implications for practice. Obstet Gynecol. 2003;102(4):685-692.

2. Breathnach FM, McAuliff FM, Geary M, et al. Perinatal Ireland Research Consortium. Optimum timing for planned delivery of uncomplicated monochorionic and dichorionic twin pregnancies. Obstet Gynecol. 2012;119(1):50-59.

3. Chasen ST, Madden A, Chervenak FA. Cesarean delivery of twins and neonatal respiratory disorders. Am J Obstet Gynecol. 1999;181(5 pt 1):1052-1056.

4. Tita AT, Landon MB, Spong CY, et al. Eunice Kennedy Shriver NICHD Maternal-Fetal Medicine Units Network. Timing of elective repeat cesarean delivery at term and neonatal outcomes. N Engl J Med. 2009;360(2):111-120.

Issue
OBG Management - 24(09)
Issue
OBG Management - 24(09)
Page Number
56-55
Page Number
56-55
Publications
Publications
Topics
Article Type
Display Headline
Is elective delivery at 37 weeks’ gestation safe in uncomplicated twin pregnancies?
Display Headline
Is elective delivery at 37 weeks’ gestation safe in uncomplicated twin pregnancies?
Legacy Keywords
Stephen T. Chasen MD;elective delivery;gestation;uncomplicated twin pregnancy;expectant management;37 weeks;timing of delivery;length of gestation;neonatal respiratory disorders;perinatal mortality;singleton;ACOG;dichorionic;monochorionic;elective cesarean delivery;birthweight;neonatal death;group B streptococcus;sepsis;ultrasonography;fetal growth;growth restriction;Examining the Evidence;induction of labor;
Legacy Keywords
Stephen T. Chasen MD;elective delivery;gestation;uncomplicated twin pregnancy;expectant management;37 weeks;timing of delivery;length of gestation;neonatal respiratory disorders;perinatal mortality;singleton;ACOG;dichorionic;monochorionic;elective cesarean delivery;birthweight;neonatal death;group B streptococcus;sepsis;ultrasonography;fetal growth;growth restriction;Examining the Evidence;induction of labor;
Sections
Article Source

PURLs Copyright

Inside the Article

Article PDF Media

Win Whitcomb: Inflexible, Big-Box EHRs Endanger the QI Movement

Article Type
Changed
Fri, 09/14/2018 - 12:22
Display Headline
Win Whitcomb: Inflexible, Big-Box EHRs Endanger the QI Movement

In “The Lean Startup,” author Eric Ries notes that in its early stages, his gaming company would routinely issue new versions of their software application several times each day. Continuous deployment—the process Ries’ company used—leveraged such Lean principles as reduced batch size and continuous learning based on end-user feedback to achieve rapid improvements in their product.

Ries says companies that learn the quickest about what the customer wants, and can incorporate that information into products more efficiently, stand the greatest chance of succeeding. A software engineer by trade, Ries uses many examples of companies that have succeeded with this approach, none of which are from healthcare.

In stark relief, the chief technology hospitalists interface with daily is the electronic health record (EHR), widely recognized as a system that fails to consider the end-user experience, that is unable to interoperate with other software, and is incapable of using data for quality improvement (QI). The PDSA (“plan, do, study, act”) cycle is the foundation of QI activities and relies on rapidly incorporating observations made by those performing the work to create novel workflows and processes based on learning. EHRs, by digitizing health information, theoretically provide the ideal tool for supporting QI.

The reality is that EHRs have been a colossal disappointment with regard to QI efforts. The space in and around EHR effectively represents “dead zones” for innovation and improvement. Mandl and Kohane note:

EHR companies have followed a business model whereby they control all data, rather than liberating the data for use in innovative applications in clinical care.

Conducting a Google-style search of an EHR database usually requires involvement of a clinician’s information services department and often the specialized knowledge and cooperation of the vendor’s technical teams.

Greg Maynard, MD, MSc, SFHM, senior vice president of SHM’s Center for Hospital Innovation and Improvement, recently provided testimony to the Office of the National Coordinator for Health Information Technology about the challenges current EHRs present to QI efforts and what features EHRs need to incorporate to better serve the needs of patients and clinicians. Dr. Maynard answered a few questions for The Hospitalist:

Q: What is it about current EHRs that make continuous improvement so difficult?

A: EHRs were built for fiscal and administrative purposes, not for quality improvement and safety. The administrative/fiscal roots of today’s IT systems lead to poor availability of clinical, quality, and safety data. In many medical centers and practices, the great majority of information available is months-old administrative data, which does not lend itself to rapid cycle improvement.

Q: Why is the PDSA cycle endangered in most systems?

A: EHRs often do not facilitate rapid-cycle, PDSA-style improvements on a small pilot scale. Most improvement teams get one shot to get the clinical decision support and data-capture tools correct after months of waiting in queue and development time. Any request for revisions and refinements is treated as a failure of the improvement team, and it is often difficult or impossible to pilot new tools in a limited setting.

Q: What features would you like to see in EHRs that would facilitate QI?

A: We need a user-friendly interface for clinicians and for data analysts/reporters. Other industries have common data formats to allow for sharing of information across disparate systems. We need the same capability for clinical information in healthcare. Also, a change in architecture of EHRs and other health IT tools that allows for not just interoperability but substitutable options is required. In the more “app”-like environment, innovation and flexibility would be the rule. An underlying architecture could have different plug-and-play modules for different functions. Some companies are overcoming the current barriers to provide wonderful, easy-to-generate and useful reports, but most are stymied by proprietary systems.

 

 

Reference

  1. Mandl KD, Kohane IS. Escaping the EHR trap: the future of health IT. N Engl J Med. 2012;366(24):2240-2242.

Dr. Whitcomb is medical director of healthcare quality at Baystate Medical Center in Springfield, Mass. He is a co-founder and past president of SHM. Email him at wfwhit@comcast.net.

Help Needed: Open Systems and Modular Architecture

Imagine all the energy we could harness if our most talented engineers wrote modular EHRs instead of “Angry Birds.”


—John Halamka, MD, chief information officer, Beth Israel Deaconess Medical Center, Boston

Today’s EHRs can be thought of as monolithic and closed, with an all-or-nothing, static set of features. On the other hand, think of your smartphone and all the apps (modules) you openly download and, if desired, you delete. This is the vision of a healthy, open, modular EHR ecosystem:

  • Imagine a busy clinician providing real-time feedback about a negative or user-hostile feature in the EHR;
  • Imagine that feedback incorporated—in days or hours—by engineers to create a new version of the application;
  • Imagine a VTE prevention QI team conducting a Google-style search of a group of patients to determine rate of pharmacologic prophylaxis and average VTE risk of that group; and
  • Imagine a hospitalist having five apps to choose from to automatically calculate the readmission risk of a patient: You could choose the best one and delete the others.

The Office of the National Coordinator for Health Information Technology has awarded a series of grants through the Strategic Health IT Advanced Research Projects (SHARP) program to help solve the vexing problems of our closed, innovation-stifling EHR environment. The output of SHARP will be “improvements in the quality, safety, and efficiency of healthcare, through advanced information technology.”

It won’t happen overnight, but perhaps we can hold out hope that there will be a day when EHRs help, not hinder, the QI process.

Issue
The Hospitalist - 2012(08)
Publications
Topics
Sections

In “The Lean Startup,” author Eric Ries notes that in its early stages, his gaming company would routinely issue new versions of their software application several times each day. Continuous deployment—the process Ries’ company used—leveraged such Lean principles as reduced batch size and continuous learning based on end-user feedback to achieve rapid improvements in their product.

Ries says companies that learn the quickest about what the customer wants, and can incorporate that information into products more efficiently, stand the greatest chance of succeeding. A software engineer by trade, Ries uses many examples of companies that have succeeded with this approach, none of which are from healthcare.

In stark relief, the chief technology hospitalists interface with daily is the electronic health record (EHR), widely recognized as a system that fails to consider the end-user experience, that is unable to interoperate with other software, and is incapable of using data for quality improvement (QI). The PDSA (“plan, do, study, act”) cycle is the foundation of QI activities and relies on rapidly incorporating observations made by those performing the work to create novel workflows and processes based on learning. EHRs, by digitizing health information, theoretically provide the ideal tool for supporting QI.

The reality is that EHRs have been a colossal disappointment with regard to QI efforts. The space in and around EHR effectively represents “dead zones” for innovation and improvement. Mandl and Kohane note:

EHR companies have followed a business model whereby they control all data, rather than liberating the data for use in innovative applications in clinical care.

Conducting a Google-style search of an EHR database usually requires involvement of a clinician’s information services department and often the specialized knowledge and cooperation of the vendor’s technical teams.

Greg Maynard, MD, MSc, SFHM, senior vice president of SHM’s Center for Hospital Innovation and Improvement, recently provided testimony to the Office of the National Coordinator for Health Information Technology about the challenges current EHRs present to QI efforts and what features EHRs need to incorporate to better serve the needs of patients and clinicians. Dr. Maynard answered a few questions for The Hospitalist:

Q: What is it about current EHRs that make continuous improvement so difficult?

A: EHRs were built for fiscal and administrative purposes, not for quality improvement and safety. The administrative/fiscal roots of today’s IT systems lead to poor availability of clinical, quality, and safety data. In many medical centers and practices, the great majority of information available is months-old administrative data, which does not lend itself to rapid cycle improvement.

Q: Why is the PDSA cycle endangered in most systems?

A: EHRs often do not facilitate rapid-cycle, PDSA-style improvements on a small pilot scale. Most improvement teams get one shot to get the clinical decision support and data-capture tools correct after months of waiting in queue and development time. Any request for revisions and refinements is treated as a failure of the improvement team, and it is often difficult or impossible to pilot new tools in a limited setting.

Q: What features would you like to see in EHRs that would facilitate QI?

A: We need a user-friendly interface for clinicians and for data analysts/reporters. Other industries have common data formats to allow for sharing of information across disparate systems. We need the same capability for clinical information in healthcare. Also, a change in architecture of EHRs and other health IT tools that allows for not just interoperability but substitutable options is required. In the more “app”-like environment, innovation and flexibility would be the rule. An underlying architecture could have different plug-and-play modules for different functions. Some companies are overcoming the current barriers to provide wonderful, easy-to-generate and useful reports, but most are stymied by proprietary systems.

 

 

Reference

  1. Mandl KD, Kohane IS. Escaping the EHR trap: the future of health IT. N Engl J Med. 2012;366(24):2240-2242.

Dr. Whitcomb is medical director of healthcare quality at Baystate Medical Center in Springfield, Mass. He is a co-founder and past president of SHM. Email him at wfwhit@comcast.net.

Help Needed: Open Systems and Modular Architecture

Imagine all the energy we could harness if our most talented engineers wrote modular EHRs instead of “Angry Birds.”


—John Halamka, MD, chief information officer, Beth Israel Deaconess Medical Center, Boston

Today’s EHRs can be thought of as monolithic and closed, with an all-or-nothing, static set of features. On the other hand, think of your smartphone and all the apps (modules) you openly download and, if desired, you delete. This is the vision of a healthy, open, modular EHR ecosystem:

  • Imagine a busy clinician providing real-time feedback about a negative or user-hostile feature in the EHR;
  • Imagine that feedback incorporated—in days or hours—by engineers to create a new version of the application;
  • Imagine a VTE prevention QI team conducting a Google-style search of a group of patients to determine rate of pharmacologic prophylaxis and average VTE risk of that group; and
  • Imagine a hospitalist having five apps to choose from to automatically calculate the readmission risk of a patient: You could choose the best one and delete the others.

The Office of the National Coordinator for Health Information Technology has awarded a series of grants through the Strategic Health IT Advanced Research Projects (SHARP) program to help solve the vexing problems of our closed, innovation-stifling EHR environment. The output of SHARP will be “improvements in the quality, safety, and efficiency of healthcare, through advanced information technology.”

It won’t happen overnight, but perhaps we can hold out hope that there will be a day when EHRs help, not hinder, the QI process.

In “The Lean Startup,” author Eric Ries notes that in its early stages, his gaming company would routinely issue new versions of their software application several times each day. Continuous deployment—the process Ries’ company used—leveraged such Lean principles as reduced batch size and continuous learning based on end-user feedback to achieve rapid improvements in their product.

Ries says companies that learn the quickest about what the customer wants, and can incorporate that information into products more efficiently, stand the greatest chance of succeeding. A software engineer by trade, Ries uses many examples of companies that have succeeded with this approach, none of which are from healthcare.

In stark relief, the chief technology hospitalists interface with daily is the electronic health record (EHR), widely recognized as a system that fails to consider the end-user experience, that is unable to interoperate with other software, and is incapable of using data for quality improvement (QI). The PDSA (“plan, do, study, act”) cycle is the foundation of QI activities and relies on rapidly incorporating observations made by those performing the work to create novel workflows and processes based on learning. EHRs, by digitizing health information, theoretically provide the ideal tool for supporting QI.

The reality is that EHRs have been a colossal disappointment with regard to QI efforts. The space in and around EHR effectively represents “dead zones” for innovation and improvement. Mandl and Kohane note:

EHR companies have followed a business model whereby they control all data, rather than liberating the data for use in innovative applications in clinical care.

Conducting a Google-style search of an EHR database usually requires involvement of a clinician’s information services department and often the specialized knowledge and cooperation of the vendor’s technical teams.

Greg Maynard, MD, MSc, SFHM, senior vice president of SHM’s Center for Hospital Innovation and Improvement, recently provided testimony to the Office of the National Coordinator for Health Information Technology about the challenges current EHRs present to QI efforts and what features EHRs need to incorporate to better serve the needs of patients and clinicians. Dr. Maynard answered a few questions for The Hospitalist:

Q: What is it about current EHRs that make continuous improvement so difficult?

A: EHRs were built for fiscal and administrative purposes, not for quality improvement and safety. The administrative/fiscal roots of today’s IT systems lead to poor availability of clinical, quality, and safety data. In many medical centers and practices, the great majority of information available is months-old administrative data, which does not lend itself to rapid cycle improvement.

Q: Why is the PDSA cycle endangered in most systems?

A: EHRs often do not facilitate rapid-cycle, PDSA-style improvements on a small pilot scale. Most improvement teams get one shot to get the clinical decision support and data-capture tools correct after months of waiting in queue and development time. Any request for revisions and refinements is treated as a failure of the improvement team, and it is often difficult or impossible to pilot new tools in a limited setting.

Q: What features would you like to see in EHRs that would facilitate QI?

A: We need a user-friendly interface for clinicians and for data analysts/reporters. Other industries have common data formats to allow for sharing of information across disparate systems. We need the same capability for clinical information in healthcare. Also, a change in architecture of EHRs and other health IT tools that allows for not just interoperability but substitutable options is required. In the more “app”-like environment, innovation and flexibility would be the rule. An underlying architecture could have different plug-and-play modules for different functions. Some companies are overcoming the current barriers to provide wonderful, easy-to-generate and useful reports, but most are stymied by proprietary systems.

 

 

Reference

  1. Mandl KD, Kohane IS. Escaping the EHR trap: the future of health IT. N Engl J Med. 2012;366(24):2240-2242.

Dr. Whitcomb is medical director of healthcare quality at Baystate Medical Center in Springfield, Mass. He is a co-founder and past president of SHM. Email him at wfwhit@comcast.net.

Help Needed: Open Systems and Modular Architecture

Imagine all the energy we could harness if our most talented engineers wrote modular EHRs instead of “Angry Birds.”


—John Halamka, MD, chief information officer, Beth Israel Deaconess Medical Center, Boston

Today’s EHRs can be thought of as monolithic and closed, with an all-or-nothing, static set of features. On the other hand, think of your smartphone and all the apps (modules) you openly download and, if desired, you delete. This is the vision of a healthy, open, modular EHR ecosystem:

  • Imagine a busy clinician providing real-time feedback about a negative or user-hostile feature in the EHR;
  • Imagine that feedback incorporated—in days or hours—by engineers to create a new version of the application;
  • Imagine a VTE prevention QI team conducting a Google-style search of a group of patients to determine rate of pharmacologic prophylaxis and average VTE risk of that group; and
  • Imagine a hospitalist having five apps to choose from to automatically calculate the readmission risk of a patient: You could choose the best one and delete the others.

The Office of the National Coordinator for Health Information Technology has awarded a series of grants through the Strategic Health IT Advanced Research Projects (SHARP) program to help solve the vexing problems of our closed, innovation-stifling EHR environment. The output of SHARP will be “improvements in the quality, safety, and efficiency of healthcare, through advanced information technology.”

It won’t happen overnight, but perhaps we can hold out hope that there will be a day when EHRs help, not hinder, the QI process.

Issue
The Hospitalist - 2012(08)
Issue
The Hospitalist - 2012(08)
Publications
Publications
Topics
Article Type
Display Headline
Win Whitcomb: Inflexible, Big-Box EHRs Endanger the QI Movement
Display Headline
Win Whitcomb: Inflexible, Big-Box EHRs Endanger the QI Movement
Sections
Disallow All Ads
Content Gating
No Gating (article Unlocked/Free)

John Nelson: Post-Discharge Calls

Article Type
Changed
Fri, 09/14/2018 - 12:22
Display Headline
John Nelson: Post-Discharge Calls

John Nelson, MD, MHM

There are lots of places to learn methods to improve patient satisfaction, including my thoughts from the January 2009 issue. Run an Internet search on “improve patient satisfaction” to get a huge number of articles, many of which have useful information and inspiration.

If you’re in a high-functioning hospitalist group, you’ve already read a lot on the topic, listened to presentations by someone at your hospital and elsewhere, and reliably reported and analyzed satisfaction survey results including HCAHPS questions and others. Maybe you’ve even engaged a consultant to help.

You might already have in place a number of strategies, such as reliably providing a business card with your photo, always sitting down in the patient’s room, asking “Is there anything else I can do?” before ending your time with a patient, etc. You’re doing all these things and more, but perhaps you’ve barely moved the needle on your satisfaction scores.

Despite your efforts, I bet your hospitalist group’s aggregate score is among the lowest of any physician group at your hospital.

You’re not alone.

What can you do about this?

I’m lucky enough to practice with some of the smartest, most professional, and most personable hospitalists you could ever meet. Yet our satisfaction scores are among the lowest for physicians at our hospital. Despite all of the improvement strategies we put in place over the last few years, our scores have barely budged.

High-Value Strategy: Phoning Patients after Discharge

I’m lucky enough to practice with some of the smartest, most professional, and most personable hospitalists you could ever meet. Yet our satisfaction scores are among the lowest for physicians at our hospital. Despite all of the improvement strategies we put in place over the last few years, our scores have barely budged. But that all changed once we instituted a formal program of phoning patients after discharge. That produced the largest uptick in our scores we’ve ever seen.

I can’t guarantee that our results are generalizable. But I have all the anecdotal information I need to be willing to invest the resources to make the calls. They improve scores. Likely more than any other single strategy. And they seem to have a positive effect on all survey questions, from how well the doctor explained things (nearly always the lowest of the HCAHPS scores for hospitalists) to the patient’s opinion of the hospital food.

Though initially resistant to expending the time and energy to make the calls, most in our group have said that they regularly feel really gratified by the response they get from patients or families. I think it is much better if a hospitalist who cared for the patient makes the calls, and I suspect (I have no proof) that calls made by a nurse or clerk are much less effective at improving patient satisfaction. And the call can serve as a valuable clinical encounter to briefly troubleshoot a problem or review a test result that was pending at discharge.

Simple Strategies

  • More than 80% of these calls should last less than three minutes. Most patients or family members will report things are going OK and thank you profusely for the call. “No doctor has ever called before,” many will say. “Can we get you the next time Mom is hospitalized?”
  • You could reduce the number of calls needed if you limit them to patients eligible for a survey; this typically is only about half of a hospitalist’s patient census. For example, patients on observation status and those discharged somewhere other than to home (e.g. to a skilled-nursing facility) are not eligible for a survey.
  • It’s usually best not to tell a patient or family to expect the call. Surprising them makes them more delighted when you do call, and a patient told to expect a call but doesn’t get one will be less satisfied than if never told to expect it. Best if no one at the hospital knows you’re making the calls, because someone might brag about you and tell the patient to expect the call.
  • For patients seen by several hospitalists, decide ahead of time which doctor makes the call. The doctor who discharged the patient is probably the simplest protocol.
  • Develop a system to track patients who have been discharged. Every morning, we get a printout of all patients discharged the prior day. We try to call all patients the day after discharge to ensure that we reach them before they’ve had a chance to complete a satisfaction survey and before the discharging doctor rotates off.
  • Develop a protocol to document the calls. Calls that lead to any new advice or therapies (e.g. see your primary-care physician sooner than planned) must be documented in the medical record, e.g., by dictating an addendum to the discharge summary. Don’t let the system get too complicated or keep you from making the calls.
  • Use your judgment about whether to call the patient or just call a family member directly; it’s often better to do the latter.
  • If you reach a voicemail (about 50% of the calls I make), leave a message and don’t keep calling back to reach a person.
 

 

Sample Scripts

Here are some simple scripts to use for post-discharge calls. If you reach the patient or family member:

  • “This is Dr. X from Superior Hospital. I was just thinking about you/your mother/your father and wanted to know how things have gone since you/she/he left the hospital.”
  • Ask about something related to the reason for their stay. “How is your appetite?” or “You haven’t had any more fever, have you?” or “Have you made your appointment with Dr. PCP yet?”
  • “I hope things go really well for you, but if you ever need the hospital again, we’d be happy to care for you at Superior Hospital.”

If you get a voicemail:

  • “This is Dr. X from Superior Hospital. I’ve been thinking about you/your mother/father since you/she/he left the hospital, and I am calling just to check on how things are going.” (For HIPPA reasons, don’t use the patient’s name when leaving a voicemail.)
  • Mention some medical concern specific to the patient, e.g., “Your culture test turned out OK and I hope you’ve been able to get the antibiotic I prescribed.”
  • “You don’t need to call me back, but if you have questions or want to provide an update, I can be reached at 555-123-4567.” (It’s very important to include this last sentence and a number where you can be reached. If omitted, many patients/families will think you must have called to convey something really important and will be distressed until able to reach you.)

Dr. Nelson has been a practicing hospitalist since 1988. He is co-founder and past president of SHM, and principal in Nelson Flores Hospital Medicine Consultants. He is co-director for SHM’s “Best Practices in Managing a Hospital Medicine Program” course.

Issue
The Hospitalist - 2012(08)
Publications
Sections

John Nelson, MD, MHM

There are lots of places to learn methods to improve patient satisfaction, including my thoughts from the January 2009 issue. Run an Internet search on “improve patient satisfaction” to get a huge number of articles, many of which have useful information and inspiration.

If you’re in a high-functioning hospitalist group, you’ve already read a lot on the topic, listened to presentations by someone at your hospital and elsewhere, and reliably reported and analyzed satisfaction survey results including HCAHPS questions and others. Maybe you’ve even engaged a consultant to help.

You might already have in place a number of strategies, such as reliably providing a business card with your photo, always sitting down in the patient’s room, asking “Is there anything else I can do?” before ending your time with a patient, etc. You’re doing all these things and more, but perhaps you’ve barely moved the needle on your satisfaction scores.

Despite your efforts, I bet your hospitalist group’s aggregate score is among the lowest of any physician group at your hospital.

You’re not alone.

What can you do about this?

I’m lucky enough to practice with some of the smartest, most professional, and most personable hospitalists you could ever meet. Yet our satisfaction scores are among the lowest for physicians at our hospital. Despite all of the improvement strategies we put in place over the last few years, our scores have barely budged.

High-Value Strategy: Phoning Patients after Discharge

I’m lucky enough to practice with some of the smartest, most professional, and most personable hospitalists you could ever meet. Yet our satisfaction scores are among the lowest for physicians at our hospital. Despite all of the improvement strategies we put in place over the last few years, our scores have barely budged. But that all changed once we instituted a formal program of phoning patients after discharge. That produced the largest uptick in our scores we’ve ever seen.

I can’t guarantee that our results are generalizable. But I have all the anecdotal information I need to be willing to invest the resources to make the calls. They improve scores. Likely more than any other single strategy. And they seem to have a positive effect on all survey questions, from how well the doctor explained things (nearly always the lowest of the HCAHPS scores for hospitalists) to the patient’s opinion of the hospital food.

Though initially resistant to expending the time and energy to make the calls, most in our group have said that they regularly feel really gratified by the response they get from patients or families. I think it is much better if a hospitalist who cared for the patient makes the calls, and I suspect (I have no proof) that calls made by a nurse or clerk are much less effective at improving patient satisfaction. And the call can serve as a valuable clinical encounter to briefly troubleshoot a problem or review a test result that was pending at discharge.

Simple Strategies

  • More than 80% of these calls should last less than three minutes. Most patients or family members will report things are going OK and thank you profusely for the call. “No doctor has ever called before,” many will say. “Can we get you the next time Mom is hospitalized?”
  • You could reduce the number of calls needed if you limit them to patients eligible for a survey; this typically is only about half of a hospitalist’s patient census. For example, patients on observation status and those discharged somewhere other than to home (e.g. to a skilled-nursing facility) are not eligible for a survey.
  • It’s usually best not to tell a patient or family to expect the call. Surprising them makes them more delighted when you do call, and a patient told to expect a call but doesn’t get one will be less satisfied than if never told to expect it. Best if no one at the hospital knows you’re making the calls, because someone might brag about you and tell the patient to expect the call.
  • For patients seen by several hospitalists, decide ahead of time which doctor makes the call. The doctor who discharged the patient is probably the simplest protocol.
  • Develop a system to track patients who have been discharged. Every morning, we get a printout of all patients discharged the prior day. We try to call all patients the day after discharge to ensure that we reach them before they’ve had a chance to complete a satisfaction survey and before the discharging doctor rotates off.
  • Develop a protocol to document the calls. Calls that lead to any new advice or therapies (e.g. see your primary-care physician sooner than planned) must be documented in the medical record, e.g., by dictating an addendum to the discharge summary. Don’t let the system get too complicated or keep you from making the calls.
  • Use your judgment about whether to call the patient or just call a family member directly; it’s often better to do the latter.
  • If you reach a voicemail (about 50% of the calls I make), leave a message and don’t keep calling back to reach a person.
 

 

Sample Scripts

Here are some simple scripts to use for post-discharge calls. If you reach the patient or family member:

  • “This is Dr. X from Superior Hospital. I was just thinking about you/your mother/your father and wanted to know how things have gone since you/she/he left the hospital.”
  • Ask about something related to the reason for their stay. “How is your appetite?” or “You haven’t had any more fever, have you?” or “Have you made your appointment with Dr. PCP yet?”
  • “I hope things go really well for you, but if you ever need the hospital again, we’d be happy to care for you at Superior Hospital.”

If you get a voicemail:

  • “This is Dr. X from Superior Hospital. I’ve been thinking about you/your mother/father since you/she/he left the hospital, and I am calling just to check on how things are going.” (For HIPPA reasons, don’t use the patient’s name when leaving a voicemail.)
  • Mention some medical concern specific to the patient, e.g., “Your culture test turned out OK and I hope you’ve been able to get the antibiotic I prescribed.”
  • “You don’t need to call me back, but if you have questions or want to provide an update, I can be reached at 555-123-4567.” (It’s very important to include this last sentence and a number where you can be reached. If omitted, many patients/families will think you must have called to convey something really important and will be distressed until able to reach you.)

Dr. Nelson has been a practicing hospitalist since 1988. He is co-founder and past president of SHM, and principal in Nelson Flores Hospital Medicine Consultants. He is co-director for SHM’s “Best Practices in Managing a Hospital Medicine Program” course.

John Nelson, MD, MHM

There are lots of places to learn methods to improve patient satisfaction, including my thoughts from the January 2009 issue. Run an Internet search on “improve patient satisfaction” to get a huge number of articles, many of which have useful information and inspiration.

If you’re in a high-functioning hospitalist group, you’ve already read a lot on the topic, listened to presentations by someone at your hospital and elsewhere, and reliably reported and analyzed satisfaction survey results including HCAHPS questions and others. Maybe you’ve even engaged a consultant to help.

You might already have in place a number of strategies, such as reliably providing a business card with your photo, always sitting down in the patient’s room, asking “Is there anything else I can do?” before ending your time with a patient, etc. You’re doing all these things and more, but perhaps you’ve barely moved the needle on your satisfaction scores.

Despite your efforts, I bet your hospitalist group’s aggregate score is among the lowest of any physician group at your hospital.

You’re not alone.

What can you do about this?

I’m lucky enough to practice with some of the smartest, most professional, and most personable hospitalists you could ever meet. Yet our satisfaction scores are among the lowest for physicians at our hospital. Despite all of the improvement strategies we put in place over the last few years, our scores have barely budged.

High-Value Strategy: Phoning Patients after Discharge

I’m lucky enough to practice with some of the smartest, most professional, and most personable hospitalists you could ever meet. Yet our satisfaction scores are among the lowest for physicians at our hospital. Despite all of the improvement strategies we put in place over the last few years, our scores have barely budged. But that all changed once we instituted a formal program of phoning patients after discharge. That produced the largest uptick in our scores we’ve ever seen.

I can’t guarantee that our results are generalizable. But I have all the anecdotal information I need to be willing to invest the resources to make the calls. They improve scores. Likely more than any other single strategy. And they seem to have a positive effect on all survey questions, from how well the doctor explained things (nearly always the lowest of the HCAHPS scores for hospitalists) to the patient’s opinion of the hospital food.

Though initially resistant to expending the time and energy to make the calls, most in our group have said that they regularly feel really gratified by the response they get from patients or families. I think it is much better if a hospitalist who cared for the patient makes the calls, and I suspect (I have no proof) that calls made by a nurse or clerk are much less effective at improving patient satisfaction. And the call can serve as a valuable clinical encounter to briefly troubleshoot a problem or review a test result that was pending at discharge.

Simple Strategies

  • More than 80% of these calls should last less than three minutes. Most patients or family members will report things are going OK and thank you profusely for the call. “No doctor has ever called before,” many will say. “Can we get you the next time Mom is hospitalized?”
  • You could reduce the number of calls needed if you limit them to patients eligible for a survey; this typically is only about half of a hospitalist’s patient census. For example, patients on observation status and those discharged somewhere other than to home (e.g. to a skilled-nursing facility) are not eligible for a survey.
  • It’s usually best not to tell a patient or family to expect the call. Surprising them makes them more delighted when you do call, and a patient told to expect a call but doesn’t get one will be less satisfied than if never told to expect it. Best if no one at the hospital knows you’re making the calls, because someone might brag about you and tell the patient to expect the call.
  • For patients seen by several hospitalists, decide ahead of time which doctor makes the call. The doctor who discharged the patient is probably the simplest protocol.
  • Develop a system to track patients who have been discharged. Every morning, we get a printout of all patients discharged the prior day. We try to call all patients the day after discharge to ensure that we reach them before they’ve had a chance to complete a satisfaction survey and before the discharging doctor rotates off.
  • Develop a protocol to document the calls. Calls that lead to any new advice or therapies (e.g. see your primary-care physician sooner than planned) must be documented in the medical record, e.g., by dictating an addendum to the discharge summary. Don’t let the system get too complicated or keep you from making the calls.
  • Use your judgment about whether to call the patient or just call a family member directly; it’s often better to do the latter.
  • If you reach a voicemail (about 50% of the calls I make), leave a message and don’t keep calling back to reach a person.
 

 

Sample Scripts

Here are some simple scripts to use for post-discharge calls. If you reach the patient or family member:

  • “This is Dr. X from Superior Hospital. I was just thinking about you/your mother/your father and wanted to know how things have gone since you/she/he left the hospital.”
  • Ask about something related to the reason for their stay. “How is your appetite?” or “You haven’t had any more fever, have you?” or “Have you made your appointment with Dr. PCP yet?”
  • “I hope things go really well for you, but if you ever need the hospital again, we’d be happy to care for you at Superior Hospital.”

If you get a voicemail:

  • “This is Dr. X from Superior Hospital. I’ve been thinking about you/your mother/father since you/she/he left the hospital, and I am calling just to check on how things are going.” (For HIPPA reasons, don’t use the patient’s name when leaving a voicemail.)
  • Mention some medical concern specific to the patient, e.g., “Your culture test turned out OK and I hope you’ve been able to get the antibiotic I prescribed.”
  • “You don’t need to call me back, but if you have questions or want to provide an update, I can be reached at 555-123-4567.” (It’s very important to include this last sentence and a number where you can be reached. If omitted, many patients/families will think you must have called to convey something really important and will be distressed until able to reach you.)

Dr. Nelson has been a practicing hospitalist since 1988. He is co-founder and past president of SHM, and principal in Nelson Flores Hospital Medicine Consultants. He is co-director for SHM’s “Best Practices in Managing a Hospital Medicine Program” course.

Issue
The Hospitalist - 2012(08)
Issue
The Hospitalist - 2012(08)
Publications
Publications
Article Type
Display Headline
John Nelson: Post-Discharge Calls
Display Headline
John Nelson: Post-Discharge Calls
Sections
Disallow All Ads
Content Gating
No Gating (article Unlocked/Free)

Does mediolateral episiotomy reduce the risk of anal sphincter injury in operative vaginal delivery?

Article Type
Changed
Tue, 08/28/2018 - 10:59
Display Headline
Does mediolateral episiotomy reduce the risk of anal sphincter injury in operative vaginal delivery?

RELATED ARTICLE

Stop performing median episiotomy!
Robert L. Barbieri, MD (Editorial, April 2012)

Episiotomy is an incision into the perineal body that is made during the second stage of labor to expedite delivery. Despite guidelines recommending restrictions on its use, episiotomy is still performed in more than 25% of vaginal deliveries in the United States. Suggested benefits include a shortened second stage of labor, the substitution of a straight surgical incision for a ragged spontaneous tear, and a reduced incidence of severe perineal injury and resultant pelvic floor dysfunction. Few data support these assertions, however.

Episiotomy is no OASIS

Absolute indications for episiotomy have yet to be established. Although there is general agreement that episiotomy may be indicated in select circumstances (such as to expedite delivery in the setting of nonreassuring fetal testing in the second stage of labor, shoulder dystocia, or at the time of operative vaginal delivery), routine use is discouraged.1,2 Besides the lack of data showing its benefit, episiotomy is associated with several potential complications, including increased blood loss, fetal injury, and localized pain. In contrast to the stated goal of reducing perineal trauma, episiotomy is associated with an increased incidence of third- or fourth-degree perineal lacerations,3,4 referred to in this study as obstetric anal sphincter injuries (OASIS).

Third- or fourth-degree tears are identified clinically at the time of vaginal delivery in 0.6% to 9% of patients.4 Studies using two-dimensional endoanal ultrasonography suggest that the true incidence of rectal injury is probably closer to 11%.5 Such injuries are associated with an increased risk of subsequent urinary or fecal incontinence (or both) and pelvic organ prolapse.

If episiotomy is indicated, how should it be performed?

There are two main types of episiotomy: median (favored in the United States) and mediolateral episiotomy. Complications—especially OASIS—are more common with median episiotomy,3,6,7 which involves a vertical midline incision from the posterior fourchette toward the rectum. Mediolateral episiotomy (favored in Europe), refers to an incision performed at a 45° angle from the posterior fourchette. OASIS is more common after median episiotomy, compared with the mediolateral approach.4,6 What is not yet clear is whether mediolateral episiotomy actually protects against OASIS.

Details of the study

de Vogel and colleagues evaluated the frequency of OASIS in women at high risk—specifically, those undergoing operative vaginal delivery; they also sought to determine whether mediolateral episiotomy is protective against OASIS. To this end, they performed a retrospective analysis of 2,861 consecutive women who delivered a singleton liveborn infant at term by vacuum, forceps, or both, from 2001–2009. Women were identified through the Netherlands Perinatal Registry, a voluntary reporting national database that includes approximately 96% of the 190,000 births that occur after 16 weeks’ gestation each year in the Netherlands. Exclusion criteria included multiple gestation, breech presentation, and use of median episiotomy.

The overall frequency of OASIS was 5.7% (162 cases among 2,861 deliveries). After logistic-regression modeling, a number of variables were significantly associated with OASIS, all of which have been identified previously: forceps delivery, occiput posterior position, primiparity, and epidural anesthesia. Women with a mediolateral episiotomy were at a significantly lower risk for OASIS, compared with women without mediolateral episiotomy (3.5% vs 15.6%, respectively; P<.001). Further analysis suggested that 8.6 mediolateral episiotomies would be needed to prevent one OASIS during vacuum extraction, whereas 5.2 procedures would be necessary to prevent one OASIS during forceps delivery. de Vogel and colleagues concluded that mediolateral episiotomy should be performed during all operative vaginal deliveries to reduce the incidence of OASIS.

Although this study included a large sample from a well-established and validated dataset (collected prospectively), it was, by design, retrospective. There was no standardization of when or how to cut the mediolateral episiotomy. However, many of these uncontrolled variables (such as cutting an episiotomy that is more median than mediolateral or cutting an episiotomy only in women who appear to be at imminent risk of sustaining a perineal laceration) would increase—not decrease—the risk of severe perineal injury. This fact suggests that the protective effect of mediolateral episiotomy may be even more dramatic than the sixfold protection reported in this study.

This study focused on women who underwent operative vaginal delivery. It remains controversial whether mediolateral episiotomy is protective in women who have a spontaneous (noninstrumental) vaginal delivery.

The study also lacks follow-up data on how many women with OASIS went on to develop fecal or urinary incontinence or pelvic organ prolapse. However, a third- or fourth-degree perineal laceration is serious enough that it can serve as an acceptable primary outcome measure even in the absence of long-term functional data.

 

 

In this study, use of median episiotomy was an exclusion, mostly likely because it is rarely performed in Europe.

WHAT THIS EVIDENCE MEANS FOR PRACTICE

While the battle over “to cut or not to cut” continues to rage, one fact is clear: median episiotomy should be abandoned. If you are going to perform episiotomy, make it mediolateral. According to this report, accoucheurs should consider cutting a mediolateral episiotomy for perineal protection each time they perform operative vaginal delivery.

ERROL R. NORWITZ, MD, PHD

TELL US …

After reading this article, and Dr. Barbieri’s April Editorial, we want to know if these articles have changed your practice. If you were faced with a difficult vaginal delivery, would you use a median or mediolateral episiotomy incision? Why?

We want to hear from you! Tell us what you think.

References

1. Hartmann K, Viswanathan M, Palmieri R, Gartlehner G, Thorp J, Lohr KN. Outcomes of routine episiotomy: a systematic review. JAMA. 2005;293(17):2141-2148.

2. Carroli G, Mignini L. Episiotomy for vaginal birth. Cochrane Database Syst Rev. 2009;(1):CD000081.-

3. Helwig JT, Thorp JM, Jr, Bowes WA, Jr. Does midline episiotomy increase the risk of third- and fourth-degree lacerations in operative vaginal deliveries? Obstet Gynecol. 1993;82(2):276-279.

4. Dudding TC, Vaizey C, Kamm MA. Obstetric anal sphincter injury: incidence, risk factors, and management. Ann Surg. 2008;247(2):224-237.

5. Williams AB, Bartram CI, Halligan S, Spencer JA, Nicholls RJ, Kmiot WA. Anal sphincter damage after vaginal delivery using three-dimensional endosonography. Obstet Gynecol. 2001;97(5 Pt 1):770-775.

6. Coats PM, Chan KK, Wilkins M, Beard RJ. A comparison between midline and mediolateral episiotomies. Br J Obstet Gynaecol. 1980;87(5):408-412.

7. Kudish B, Blackwell S, McNeeley SG, et al. Operative vaginal delivery and midline episiotomy: a bad combination for the perineum. Am J Obstet Gynecol. 2006;195(3):749-754.

Article PDF
Author and Disclosure Information

EXPERT COMMENTARY

Errol R. Norwitz, MD, PhD
Louis E. Phaneuf Professor of Obstetrics and Gynecology, Tufts University School of Medicine, and Chairman, Department of Obstetrics and Gynecology, Tufts Medical Center, Boston, Massachusetts. Dr. Norwitz serves on the OBG Management Board of Editors.

Issue
OBG Management - 24(08)
Publications
Topics
Page Number
56-55
Legacy Keywords
Errol Norwitz MD;mediolateral episiotomy;anal sphincter injury;operative vaginal delivery;median episiotomy;episiotomy;pelvic floor dysfunction;fecal incontinence;urinary incontinence;shoulder dystocia;increased blood loss;fetal injury;localized pain;perineal trauma;perineal laceration;obstetric anal sphincter injuries;OASIS;endoanal ultrasonography;posterior fourchette;rectum;vacuum extraction;forceps;breech presentation;multiple gestation;primiparity;epidural;spontaneous vaginal delivery;
Sections
Author and Disclosure Information

EXPERT COMMENTARY

Errol R. Norwitz, MD, PhD
Louis E. Phaneuf Professor of Obstetrics and Gynecology, Tufts University School of Medicine, and Chairman, Department of Obstetrics and Gynecology, Tufts Medical Center, Boston, Massachusetts. Dr. Norwitz serves on the OBG Management Board of Editors.

Author and Disclosure Information

EXPERT COMMENTARY

Errol R. Norwitz, MD, PhD
Louis E. Phaneuf Professor of Obstetrics and Gynecology, Tufts University School of Medicine, and Chairman, Department of Obstetrics and Gynecology, Tufts Medical Center, Boston, Massachusetts. Dr. Norwitz serves on the OBG Management Board of Editors.

Article PDF
Article PDF

RELATED ARTICLE

Stop performing median episiotomy!
Robert L. Barbieri, MD (Editorial, April 2012)

Episiotomy is an incision into the perineal body that is made during the second stage of labor to expedite delivery. Despite guidelines recommending restrictions on its use, episiotomy is still performed in more than 25% of vaginal deliveries in the United States. Suggested benefits include a shortened second stage of labor, the substitution of a straight surgical incision for a ragged spontaneous tear, and a reduced incidence of severe perineal injury and resultant pelvic floor dysfunction. Few data support these assertions, however.

Episiotomy is no OASIS

Absolute indications for episiotomy have yet to be established. Although there is general agreement that episiotomy may be indicated in select circumstances (such as to expedite delivery in the setting of nonreassuring fetal testing in the second stage of labor, shoulder dystocia, or at the time of operative vaginal delivery), routine use is discouraged.1,2 Besides the lack of data showing its benefit, episiotomy is associated with several potential complications, including increased blood loss, fetal injury, and localized pain. In contrast to the stated goal of reducing perineal trauma, episiotomy is associated with an increased incidence of third- or fourth-degree perineal lacerations,3,4 referred to in this study as obstetric anal sphincter injuries (OASIS).

Third- or fourth-degree tears are identified clinically at the time of vaginal delivery in 0.6% to 9% of patients.4 Studies using two-dimensional endoanal ultrasonography suggest that the true incidence of rectal injury is probably closer to 11%.5 Such injuries are associated with an increased risk of subsequent urinary or fecal incontinence (or both) and pelvic organ prolapse.

If episiotomy is indicated, how should it be performed?

There are two main types of episiotomy: median (favored in the United States) and mediolateral episiotomy. Complications—especially OASIS—are more common with median episiotomy,3,6,7 which involves a vertical midline incision from the posterior fourchette toward the rectum. Mediolateral episiotomy (favored in Europe), refers to an incision performed at a 45° angle from the posterior fourchette. OASIS is more common after median episiotomy, compared with the mediolateral approach.4,6 What is not yet clear is whether mediolateral episiotomy actually protects against OASIS.

Details of the study

de Vogel and colleagues evaluated the frequency of OASIS in women at high risk—specifically, those undergoing operative vaginal delivery; they also sought to determine whether mediolateral episiotomy is protective against OASIS. To this end, they performed a retrospective analysis of 2,861 consecutive women who delivered a singleton liveborn infant at term by vacuum, forceps, or both, from 2001–2009. Women were identified through the Netherlands Perinatal Registry, a voluntary reporting national database that includes approximately 96% of the 190,000 births that occur after 16 weeks’ gestation each year in the Netherlands. Exclusion criteria included multiple gestation, breech presentation, and use of median episiotomy.

The overall frequency of OASIS was 5.7% (162 cases among 2,861 deliveries). After logistic-regression modeling, a number of variables were significantly associated with OASIS, all of which have been identified previously: forceps delivery, occiput posterior position, primiparity, and epidural anesthesia. Women with a mediolateral episiotomy were at a significantly lower risk for OASIS, compared with women without mediolateral episiotomy (3.5% vs 15.6%, respectively; P<.001). Further analysis suggested that 8.6 mediolateral episiotomies would be needed to prevent one OASIS during vacuum extraction, whereas 5.2 procedures would be necessary to prevent one OASIS during forceps delivery. de Vogel and colleagues concluded that mediolateral episiotomy should be performed during all operative vaginal deliveries to reduce the incidence of OASIS.

Although this study included a large sample from a well-established and validated dataset (collected prospectively), it was, by design, retrospective. There was no standardization of when or how to cut the mediolateral episiotomy. However, many of these uncontrolled variables (such as cutting an episiotomy that is more median than mediolateral or cutting an episiotomy only in women who appear to be at imminent risk of sustaining a perineal laceration) would increase—not decrease—the risk of severe perineal injury. This fact suggests that the protective effect of mediolateral episiotomy may be even more dramatic than the sixfold protection reported in this study.

This study focused on women who underwent operative vaginal delivery. It remains controversial whether mediolateral episiotomy is protective in women who have a spontaneous (noninstrumental) vaginal delivery.

The study also lacks follow-up data on how many women with OASIS went on to develop fecal or urinary incontinence or pelvic organ prolapse. However, a third- or fourth-degree perineal laceration is serious enough that it can serve as an acceptable primary outcome measure even in the absence of long-term functional data.

 

 

In this study, use of median episiotomy was an exclusion, mostly likely because it is rarely performed in Europe.

WHAT THIS EVIDENCE MEANS FOR PRACTICE

While the battle over “to cut or not to cut” continues to rage, one fact is clear: median episiotomy should be abandoned. If you are going to perform episiotomy, make it mediolateral. According to this report, accoucheurs should consider cutting a mediolateral episiotomy for perineal protection each time they perform operative vaginal delivery.

ERROL R. NORWITZ, MD, PHD

TELL US …

After reading this article, and Dr. Barbieri’s April Editorial, we want to know if these articles have changed your practice. If you were faced with a difficult vaginal delivery, would you use a median or mediolateral episiotomy incision? Why?

We want to hear from you! Tell us what you think.

RELATED ARTICLE

Stop performing median episiotomy!
Robert L. Barbieri, MD (Editorial, April 2012)

Episiotomy is an incision into the perineal body that is made during the second stage of labor to expedite delivery. Despite guidelines recommending restrictions on its use, episiotomy is still performed in more than 25% of vaginal deliveries in the United States. Suggested benefits include a shortened second stage of labor, the substitution of a straight surgical incision for a ragged spontaneous tear, and a reduced incidence of severe perineal injury and resultant pelvic floor dysfunction. Few data support these assertions, however.

Episiotomy is no OASIS

Absolute indications for episiotomy have yet to be established. Although there is general agreement that episiotomy may be indicated in select circumstances (such as to expedite delivery in the setting of nonreassuring fetal testing in the second stage of labor, shoulder dystocia, or at the time of operative vaginal delivery), routine use is discouraged.1,2 Besides the lack of data showing its benefit, episiotomy is associated with several potential complications, including increased blood loss, fetal injury, and localized pain. In contrast to the stated goal of reducing perineal trauma, episiotomy is associated with an increased incidence of third- or fourth-degree perineal lacerations,3,4 referred to in this study as obstetric anal sphincter injuries (OASIS).

Third- or fourth-degree tears are identified clinically at the time of vaginal delivery in 0.6% to 9% of patients.4 Studies using two-dimensional endoanal ultrasonography suggest that the true incidence of rectal injury is probably closer to 11%.5 Such injuries are associated with an increased risk of subsequent urinary or fecal incontinence (or both) and pelvic organ prolapse.

If episiotomy is indicated, how should it be performed?

There are two main types of episiotomy: median (favored in the United States) and mediolateral episiotomy. Complications—especially OASIS—are more common with median episiotomy,3,6,7 which involves a vertical midline incision from the posterior fourchette toward the rectum. Mediolateral episiotomy (favored in Europe), refers to an incision performed at a 45° angle from the posterior fourchette. OASIS is more common after median episiotomy, compared with the mediolateral approach.4,6 What is not yet clear is whether mediolateral episiotomy actually protects against OASIS.

Details of the study

de Vogel and colleagues evaluated the frequency of OASIS in women at high risk—specifically, those undergoing operative vaginal delivery; they also sought to determine whether mediolateral episiotomy is protective against OASIS. To this end, they performed a retrospective analysis of 2,861 consecutive women who delivered a singleton liveborn infant at term by vacuum, forceps, or both, from 2001–2009. Women were identified through the Netherlands Perinatal Registry, a voluntary reporting national database that includes approximately 96% of the 190,000 births that occur after 16 weeks’ gestation each year in the Netherlands. Exclusion criteria included multiple gestation, breech presentation, and use of median episiotomy.

The overall frequency of OASIS was 5.7% (162 cases among 2,861 deliveries). After logistic-regression modeling, a number of variables were significantly associated with OASIS, all of which have been identified previously: forceps delivery, occiput posterior position, primiparity, and epidural anesthesia. Women with a mediolateral episiotomy were at a significantly lower risk for OASIS, compared with women without mediolateral episiotomy (3.5% vs 15.6%, respectively; P<.001). Further analysis suggested that 8.6 mediolateral episiotomies would be needed to prevent one OASIS during vacuum extraction, whereas 5.2 procedures would be necessary to prevent one OASIS during forceps delivery. de Vogel and colleagues concluded that mediolateral episiotomy should be performed during all operative vaginal deliveries to reduce the incidence of OASIS.

Although this study included a large sample from a well-established and validated dataset (collected prospectively), it was, by design, retrospective. There was no standardization of when or how to cut the mediolateral episiotomy. However, many of these uncontrolled variables (such as cutting an episiotomy that is more median than mediolateral or cutting an episiotomy only in women who appear to be at imminent risk of sustaining a perineal laceration) would increase—not decrease—the risk of severe perineal injury. This fact suggests that the protective effect of mediolateral episiotomy may be even more dramatic than the sixfold protection reported in this study.

This study focused on women who underwent operative vaginal delivery. It remains controversial whether mediolateral episiotomy is protective in women who have a spontaneous (noninstrumental) vaginal delivery.

The study also lacks follow-up data on how many women with OASIS went on to develop fecal or urinary incontinence or pelvic organ prolapse. However, a third- or fourth-degree perineal laceration is serious enough that it can serve as an acceptable primary outcome measure even in the absence of long-term functional data.

 

 

In this study, use of median episiotomy was an exclusion, mostly likely because it is rarely performed in Europe.

WHAT THIS EVIDENCE MEANS FOR PRACTICE

While the battle over “to cut or not to cut” continues to rage, one fact is clear: median episiotomy should be abandoned. If you are going to perform episiotomy, make it mediolateral. According to this report, accoucheurs should consider cutting a mediolateral episiotomy for perineal protection each time they perform operative vaginal delivery.

ERROL R. NORWITZ, MD, PHD

TELL US …

After reading this article, and Dr. Barbieri’s April Editorial, we want to know if these articles have changed your practice. If you were faced with a difficult vaginal delivery, would you use a median or mediolateral episiotomy incision? Why?

We want to hear from you! Tell us what you think.

References

1. Hartmann K, Viswanathan M, Palmieri R, Gartlehner G, Thorp J, Lohr KN. Outcomes of routine episiotomy: a systematic review. JAMA. 2005;293(17):2141-2148.

2. Carroli G, Mignini L. Episiotomy for vaginal birth. Cochrane Database Syst Rev. 2009;(1):CD000081.-

3. Helwig JT, Thorp JM, Jr, Bowes WA, Jr. Does midline episiotomy increase the risk of third- and fourth-degree lacerations in operative vaginal deliveries? Obstet Gynecol. 1993;82(2):276-279.

4. Dudding TC, Vaizey C, Kamm MA. Obstetric anal sphincter injury: incidence, risk factors, and management. Ann Surg. 2008;247(2):224-237.

5. Williams AB, Bartram CI, Halligan S, Spencer JA, Nicholls RJ, Kmiot WA. Anal sphincter damage after vaginal delivery using three-dimensional endosonography. Obstet Gynecol. 2001;97(5 Pt 1):770-775.

6. Coats PM, Chan KK, Wilkins M, Beard RJ. A comparison between midline and mediolateral episiotomies. Br J Obstet Gynaecol. 1980;87(5):408-412.

7. Kudish B, Blackwell S, McNeeley SG, et al. Operative vaginal delivery and midline episiotomy: a bad combination for the perineum. Am J Obstet Gynecol. 2006;195(3):749-754.

References

1. Hartmann K, Viswanathan M, Palmieri R, Gartlehner G, Thorp J, Lohr KN. Outcomes of routine episiotomy: a systematic review. JAMA. 2005;293(17):2141-2148.

2. Carroli G, Mignini L. Episiotomy for vaginal birth. Cochrane Database Syst Rev. 2009;(1):CD000081.-

3. Helwig JT, Thorp JM, Jr, Bowes WA, Jr. Does midline episiotomy increase the risk of third- and fourth-degree lacerations in operative vaginal deliveries? Obstet Gynecol. 1993;82(2):276-279.

4. Dudding TC, Vaizey C, Kamm MA. Obstetric anal sphincter injury: incidence, risk factors, and management. Ann Surg. 2008;247(2):224-237.

5. Williams AB, Bartram CI, Halligan S, Spencer JA, Nicholls RJ, Kmiot WA. Anal sphincter damage after vaginal delivery using three-dimensional endosonography. Obstet Gynecol. 2001;97(5 Pt 1):770-775.

6. Coats PM, Chan KK, Wilkins M, Beard RJ. A comparison between midline and mediolateral episiotomies. Br J Obstet Gynaecol. 1980;87(5):408-412.

7. Kudish B, Blackwell S, McNeeley SG, et al. Operative vaginal delivery and midline episiotomy: a bad combination for the perineum. Am J Obstet Gynecol. 2006;195(3):749-754.

Issue
OBG Management - 24(08)
Issue
OBG Management - 24(08)
Page Number
56-55
Page Number
56-55
Publications
Publications
Topics
Article Type
Display Headline
Does mediolateral episiotomy reduce the risk of anal sphincter injury in operative vaginal delivery?
Display Headline
Does mediolateral episiotomy reduce the risk of anal sphincter injury in operative vaginal delivery?
Legacy Keywords
Errol Norwitz MD;mediolateral episiotomy;anal sphincter injury;operative vaginal delivery;median episiotomy;episiotomy;pelvic floor dysfunction;fecal incontinence;urinary incontinence;shoulder dystocia;increased blood loss;fetal injury;localized pain;perineal trauma;perineal laceration;obstetric anal sphincter injuries;OASIS;endoanal ultrasonography;posterior fourchette;rectum;vacuum extraction;forceps;breech presentation;multiple gestation;primiparity;epidural;spontaneous vaginal delivery;
Legacy Keywords
Errol Norwitz MD;mediolateral episiotomy;anal sphincter injury;operative vaginal delivery;median episiotomy;episiotomy;pelvic floor dysfunction;fecal incontinence;urinary incontinence;shoulder dystocia;increased blood loss;fetal injury;localized pain;perineal trauma;perineal laceration;obstetric anal sphincter injuries;OASIS;endoanal ultrasonography;posterior fourchette;rectum;vacuum extraction;forceps;breech presentation;multiple gestation;primiparity;epidural;spontaneous vaginal delivery;
Sections
Article Source

PURLs Copyright

Inside the Article

Article PDF Media

What is the optimal interval for osteoporosis screening in postmenopausal women before fracture occurrence and osteoporosis treatment initiation?

Article Type
Changed
Tue, 08/28/2018 - 10:59
Display Headline
What is the optimal interval for osteoporosis screening in postmenopausal women before fracture occurrence and osteoporosis treatment initiation?

RELATED ARTICLE

Update on Osteoporosis
Steven R. Goldstein, MD (November 2011)

The optimal screening interval for bone density assessment in menopausal women is an extremely complicated but important issue because osteoporosis and fragility fracture are a major health concern. There are nearly 2 million osteoporotic fractures each year, accounting for 432,000 hospital admissions, 25 million office visits, and an increased risk of disability and death, all at a cost of up to $18 billion.1

There is no question that determination of bone mass (achieved through bone mineral density [BMD] testing by dual energy x-ray absorptiometry [DXA] and reported as T scores) will diagnose osteopenia and osteoporosis, correlate with fracture risk (the lower the bone mass, the higher the incidence of fracture), and monitor changes in bone mass over time.

Medicare allows for BMD testing every 23 months, and that has become standard for many clinicians.

Details of the trial

Gourlay and colleagues studied nearly 5,000 basically healthy women, the youngest of whom was 67 years of age. Women who had osteoporosis and who were taking medication for fracture reduction were excluded, as were women who had a history of pre-existing fracture.

The researchers concluded that the better the initial bone-density score at age 67, the longer it would take for a woman to develop osteoporosis. For instance, if a woman older than 67 years had a T score of –1.00 or better, it would take her 16.8 years (95% confidence interval [CI], 11.5 to 24.6) to reach osteoporosis. In contrast, a woman with a T score of –2.00 would reach osteoporosis in only 1.1 years. Current estrogen use was found to be significantly associated with higher BMD and a longer testing interval, although the authors did not recommend modifying the screening interval on the basis of estrogen use.

These findings certainly call into question the notion that all patients should be screened for osteoporosis every 23 months. Perhaps it is better to think of screening as a way to initially triage patients for decisions relative to follow-up.

Limitations and considerations

Some extremely important observations must be made:

  • The article by Gourlay and colleagues created tremendous media attention, most of which implied that there is too much screening with DXA scans. Nothing can be further from the truth. Only 13% of women older than age 65 are actually getting a baseline DXA scan.2
  • The data in this report apply only to white women older than 67 years who have no pre-existing fracture and are not taking any medications for osteoporosis. Extrapolation to younger women or other groups is not valid.
  • We should not be interested in the development of an arbitrary T score for bone mass but rather the determination of whether a particular patient has a level of fracture risk that warrants pharmacologic intervention.

These observations support use of a model like FRAX (see “What is FRAX?”), which can be used annually even without an updated DXA of the hip. FRAX is much more appropriate than DXA testing every 23 months and should become the clinical standard of care.

What is FRAX?

The Fracture Risk Assessment (FRAX®) Tool1 has been developed by the World Health Organization (WHO). It is based on individual patient models that integrate the risks associated with clinical factors as well as bone mineral density at the femoral neck. FRAX models have been developed from studying population-based cohorts from Europe, North America, Asia, and Australia.

FRAX algorithms give the 10-year probability of hip fracture and of a major osteoporotic fracture (clinical spine, forearm, hip, or shoulder fracture).

WHO offers sophisticated computer-driven models or simplified, printable versions of FRAX for office use—available at http://www.who-frax.org/.

Reference

1. Welcome to FRAX. FRAX: WHO Fracture Risk Assessment Tool Web site. http://www.shef.ac.uk/FRAX/. Accessed July 7, 2012.

Remember, there are more fragility fractures in nonosteoporotic women than in osteoporotic women. The risk (incidence per 10,000 women) is greater in osteoporotic women, but the absolute number in the population is greater in women who have not yet reached that threshold.

WHAT THIS EVIDENCE MEANS FOR PRACTICE

In older healthy women, BMD follow-up arbitrarily at 23 months makes little sense. The interval before reassessment can substantially lengthen for some women with excellent initial T scores, while more frequent assessments should be performed for women with worse initial T scores. Furthermore, strict reliance solely on T scores is not the best method for predicting fracture risk or when to start pharmacologic intervention. Yearly assessment using a tool like FRAX should become the standard.

STEVEN R. GOLDSTEIN, MD

We want to hear from you! Tell us what you think.

References

1. Lewiecki EM, Laster AJ, Miller PF, Bilezikian JP. More bone density testing is needed, not less. J Bone Miner Res. 2012;27(4):739-742.

2. American Society for Bone and Mineral Research. The American Society for Bone and Mineral Research response to media coverage of New England Journal of Medicine study: “Bone Density Testing Interval and Transition to osteoporosis in older women.” http://www.asbmr.org/about/pressreleases/detail.aspx?cid=3801baff-0df3-47c0-874f-08a185d67001. Published February 1, 2012. Accessed April 9, 2012.

Article PDF
Author and Disclosure Information

EXPERT COMMENTARY

Steven R. Goldstein, MD
Professor, Department of Obstetrics and Gynecology, New York University School of Medicine, and Director, Gynecologic Ultrasound, and Co-Director, Bone Densitometry, New York University Medical Center, New York. He serves on the OBG Management Board of Editors.

Issue
OBG Management - 24(08)
Publications
Topics
Page Number
56-55
Legacy Keywords
Steven R. Goldstein MD;osteoporosis;postmenopausal women;fracture occurrence;osteoporosis treatment;osteoporosis screening;bone mineral density;BMD;osteopenia;bone mass;dual energy x-ray absorptiometry;DXA;T score;Medicare;pharmacologic intervention;FRAX;Fracture Risk Assessment;World Health Organization;WHO;hip fracture;major osteoporotic fracture;spine;forearm;hip;shoulder;fragility fracture;nonosteoporotic women;
Sections
Author and Disclosure Information

EXPERT COMMENTARY

Steven R. Goldstein, MD
Professor, Department of Obstetrics and Gynecology, New York University School of Medicine, and Director, Gynecologic Ultrasound, and Co-Director, Bone Densitometry, New York University Medical Center, New York. He serves on the OBG Management Board of Editors.

Author and Disclosure Information

EXPERT COMMENTARY

Steven R. Goldstein, MD
Professor, Department of Obstetrics and Gynecology, New York University School of Medicine, and Director, Gynecologic Ultrasound, and Co-Director, Bone Densitometry, New York University Medical Center, New York. He serves on the OBG Management Board of Editors.

Article PDF
Article PDF

RELATED ARTICLE

Update on Osteoporosis
Steven R. Goldstein, MD (November 2011)

The optimal screening interval for bone density assessment in menopausal women is an extremely complicated but important issue because osteoporosis and fragility fracture are a major health concern. There are nearly 2 million osteoporotic fractures each year, accounting for 432,000 hospital admissions, 25 million office visits, and an increased risk of disability and death, all at a cost of up to $18 billion.1

There is no question that determination of bone mass (achieved through bone mineral density [BMD] testing by dual energy x-ray absorptiometry [DXA] and reported as T scores) will diagnose osteopenia and osteoporosis, correlate with fracture risk (the lower the bone mass, the higher the incidence of fracture), and monitor changes in bone mass over time.

Medicare allows for BMD testing every 23 months, and that has become standard for many clinicians.

Details of the trial

Gourlay and colleagues studied nearly 5,000 basically healthy women, the youngest of whom was 67 years of age. Women who had osteoporosis and who were taking medication for fracture reduction were excluded, as were women who had a history of pre-existing fracture.

The researchers concluded that the better the initial bone-density score at age 67, the longer it would take for a woman to develop osteoporosis. For instance, if a woman older than 67 years had a T score of –1.00 or better, it would take her 16.8 years (95% confidence interval [CI], 11.5 to 24.6) to reach osteoporosis. In contrast, a woman with a T score of –2.00 would reach osteoporosis in only 1.1 years. Current estrogen use was found to be significantly associated with higher BMD and a longer testing interval, although the authors did not recommend modifying the screening interval on the basis of estrogen use.

These findings certainly call into question the notion that all patients should be screened for osteoporosis every 23 months. Perhaps it is better to think of screening as a way to initially triage patients for decisions relative to follow-up.

Limitations and considerations

Some extremely important observations must be made:

  • The article by Gourlay and colleagues created tremendous media attention, most of which implied that there is too much screening with DXA scans. Nothing can be further from the truth. Only 13% of women older than age 65 are actually getting a baseline DXA scan.2
  • The data in this report apply only to white women older than 67 years who have no pre-existing fracture and are not taking any medications for osteoporosis. Extrapolation to younger women or other groups is not valid.
  • We should not be interested in the development of an arbitrary T score for bone mass but rather the determination of whether a particular patient has a level of fracture risk that warrants pharmacologic intervention.

These observations support use of a model like FRAX (see “What is FRAX?”), which can be used annually even without an updated DXA of the hip. FRAX is much more appropriate than DXA testing every 23 months and should become the clinical standard of care.

What is FRAX?

The Fracture Risk Assessment (FRAX®) Tool1 has been developed by the World Health Organization (WHO). It is based on individual patient models that integrate the risks associated with clinical factors as well as bone mineral density at the femoral neck. FRAX models have been developed from studying population-based cohorts from Europe, North America, Asia, and Australia.

FRAX algorithms give the 10-year probability of hip fracture and of a major osteoporotic fracture (clinical spine, forearm, hip, or shoulder fracture).

WHO offers sophisticated computer-driven models or simplified, printable versions of FRAX for office use—available at http://www.who-frax.org/.

Reference

1. Welcome to FRAX. FRAX: WHO Fracture Risk Assessment Tool Web site. http://www.shef.ac.uk/FRAX/. Accessed July 7, 2012.

Remember, there are more fragility fractures in nonosteoporotic women than in osteoporotic women. The risk (incidence per 10,000 women) is greater in osteoporotic women, but the absolute number in the population is greater in women who have not yet reached that threshold.

WHAT THIS EVIDENCE MEANS FOR PRACTICE

In older healthy women, BMD follow-up arbitrarily at 23 months makes little sense. The interval before reassessment can substantially lengthen for some women with excellent initial T scores, while more frequent assessments should be performed for women with worse initial T scores. Furthermore, strict reliance solely on T scores is not the best method for predicting fracture risk or when to start pharmacologic intervention. Yearly assessment using a tool like FRAX should become the standard.

STEVEN R. GOLDSTEIN, MD

We want to hear from you! Tell us what you think.

RELATED ARTICLE

Update on Osteoporosis
Steven R. Goldstein, MD (November 2011)

The optimal screening interval for bone density assessment in menopausal women is an extremely complicated but important issue because osteoporosis and fragility fracture are a major health concern. There are nearly 2 million osteoporotic fractures each year, accounting for 432,000 hospital admissions, 25 million office visits, and an increased risk of disability and death, all at a cost of up to $18 billion.1

There is no question that determination of bone mass (achieved through bone mineral density [BMD] testing by dual energy x-ray absorptiometry [DXA] and reported as T scores) will diagnose osteopenia and osteoporosis, correlate with fracture risk (the lower the bone mass, the higher the incidence of fracture), and monitor changes in bone mass over time.

Medicare allows for BMD testing every 23 months, and that has become standard for many clinicians.

Details of the trial

Gourlay and colleagues studied nearly 5,000 basically healthy women, the youngest of whom was 67 years of age. Women who had osteoporosis and who were taking medication for fracture reduction were excluded, as were women who had a history of pre-existing fracture.

The researchers concluded that the better the initial bone-density score at age 67, the longer it would take for a woman to develop osteoporosis. For instance, if a woman older than 67 years had a T score of –1.00 or better, it would take her 16.8 years (95% confidence interval [CI], 11.5 to 24.6) to reach osteoporosis. In contrast, a woman with a T score of –2.00 would reach osteoporosis in only 1.1 years. Current estrogen use was found to be significantly associated with higher BMD and a longer testing interval, although the authors did not recommend modifying the screening interval on the basis of estrogen use.

These findings certainly call into question the notion that all patients should be screened for osteoporosis every 23 months. Perhaps it is better to think of screening as a way to initially triage patients for decisions relative to follow-up.

Limitations and considerations

Some extremely important observations must be made:

  • The article by Gourlay and colleagues created tremendous media attention, most of which implied that there is too much screening with DXA scans. Nothing can be further from the truth. Only 13% of women older than age 65 are actually getting a baseline DXA scan.2
  • The data in this report apply only to white women older than 67 years who have no pre-existing fracture and are not taking any medications for osteoporosis. Extrapolation to younger women or other groups is not valid.
  • We should not be interested in the development of an arbitrary T score for bone mass but rather the determination of whether a particular patient has a level of fracture risk that warrants pharmacologic intervention.

These observations support use of a model like FRAX (see “What is FRAX?”), which can be used annually even without an updated DXA of the hip. FRAX is much more appropriate than DXA testing every 23 months and should become the clinical standard of care.

What is FRAX?

The Fracture Risk Assessment (FRAX®) Tool1 has been developed by the World Health Organization (WHO). It is based on individual patient models that integrate the risks associated with clinical factors as well as bone mineral density at the femoral neck. FRAX models have been developed from studying population-based cohorts from Europe, North America, Asia, and Australia.

FRAX algorithms give the 10-year probability of hip fracture and of a major osteoporotic fracture (clinical spine, forearm, hip, or shoulder fracture).

WHO offers sophisticated computer-driven models or simplified, printable versions of FRAX for office use—available at http://www.who-frax.org/.

Reference

1. Welcome to FRAX. FRAX: WHO Fracture Risk Assessment Tool Web site. http://www.shef.ac.uk/FRAX/. Accessed July 7, 2012.

Remember, there are more fragility fractures in nonosteoporotic women than in osteoporotic women. The risk (incidence per 10,000 women) is greater in osteoporotic women, but the absolute number in the population is greater in women who have not yet reached that threshold.

WHAT THIS EVIDENCE MEANS FOR PRACTICE

In older healthy women, BMD follow-up arbitrarily at 23 months makes little sense. The interval before reassessment can substantially lengthen for some women with excellent initial T scores, while more frequent assessments should be performed for women with worse initial T scores. Furthermore, strict reliance solely on T scores is not the best method for predicting fracture risk or when to start pharmacologic intervention. Yearly assessment using a tool like FRAX should become the standard.

STEVEN R. GOLDSTEIN, MD

We want to hear from you! Tell us what you think.

References

1. Lewiecki EM, Laster AJ, Miller PF, Bilezikian JP. More bone density testing is needed, not less. J Bone Miner Res. 2012;27(4):739-742.

2. American Society for Bone and Mineral Research. The American Society for Bone and Mineral Research response to media coverage of New England Journal of Medicine study: “Bone Density Testing Interval and Transition to osteoporosis in older women.” http://www.asbmr.org/about/pressreleases/detail.aspx?cid=3801baff-0df3-47c0-874f-08a185d67001. Published February 1, 2012. Accessed April 9, 2012.

References

1. Lewiecki EM, Laster AJ, Miller PF, Bilezikian JP. More bone density testing is needed, not less. J Bone Miner Res. 2012;27(4):739-742.

2. American Society for Bone and Mineral Research. The American Society for Bone and Mineral Research response to media coverage of New England Journal of Medicine study: “Bone Density Testing Interval and Transition to osteoporosis in older women.” http://www.asbmr.org/about/pressreleases/detail.aspx?cid=3801baff-0df3-47c0-874f-08a185d67001. Published February 1, 2012. Accessed April 9, 2012.

Issue
OBG Management - 24(08)
Issue
OBG Management - 24(08)
Page Number
56-55
Page Number
56-55
Publications
Publications
Topics
Article Type
Display Headline
What is the optimal interval for osteoporosis screening in postmenopausal women before fracture occurrence and osteoporosis treatment initiation?
Display Headline
What is the optimal interval for osteoporosis screening in postmenopausal women before fracture occurrence and osteoporosis treatment initiation?
Legacy Keywords
Steven R. Goldstein MD;osteoporosis;postmenopausal women;fracture occurrence;osteoporosis treatment;osteoporosis screening;bone mineral density;BMD;osteopenia;bone mass;dual energy x-ray absorptiometry;DXA;T score;Medicare;pharmacologic intervention;FRAX;Fracture Risk Assessment;World Health Organization;WHO;hip fracture;major osteoporotic fracture;spine;forearm;hip;shoulder;fragility fracture;nonosteoporotic women;
Legacy Keywords
Steven R. Goldstein MD;osteoporosis;postmenopausal women;fracture occurrence;osteoporosis treatment;osteoporosis screening;bone mineral density;BMD;osteopenia;bone mass;dual energy x-ray absorptiometry;DXA;T score;Medicare;pharmacologic intervention;FRAX;Fracture Risk Assessment;World Health Organization;WHO;hip fracture;major osteoporotic fracture;spine;forearm;hip;shoulder;fragility fracture;nonosteoporotic women;
Sections
Article Source

PURLs Copyright

Inside the Article

Article PDF Media

Win Whitcomb: Spotlight on Medical Necessity

Article Type
Changed
Fri, 09/14/2018 - 12:22
Display Headline
Win Whitcomb: Spotlight on Medical Necessity

EDITOR’S NOTE: An incorrect version of Win Whitcomb’s “On the Horizon” column was published in the July issue of The Hospitalist. We deeply regret the error. The correct version of Dr. Whitcomb’s column appears this month, with proper attribution given to hospitalist Brad Flansbaum, DO, SFHM, who contributed to the column.

Assigning the appropriate status to patients (“inpatient” or “observation”) has emerged as a front-and-center issue for hospitalists. Also known as “medical necessity,” many HM groups have been called upon to help solve the “status” problem for their institutions. With nearly 1 in 5 hospitalized patients on observation status in U.S. hospitals, appropriately assigning status is now a dominant, system-level challenge for hospitalists.

This month, we asked two experts to shed light on the nature of this beast, with a focus on the impact on the patient. Brad Flansbaum, DO, SFHM, hospitalist at Lenox Hill Hospital in New York City, and Patrick Conway, MD, FAAP, MSC, SFHM, chief medical officer at the Centers for Medicare & Medicaid Services (CMS), were kind enough to participate in the interview. We start with Dr. Flansbaum.

Dr. Whitcomb: It appears that patients are caught in the middle of the observation status challenge, at least as it relates to footing the bill. Explain the patient perspective of being unwittingly placed on observation status.

Dr. Flansbaum: Recall your last credit card statement. On it is the hotel charge from your last out-of-town CME excursion. Below the total charge, which you were expecting, is a separate line item for a $75 “recreational fee.” You call the hotel, and they inform you that, because you used the hotel gym and pool—accessed with your room key, they levied the fee. No signs, alerts, or postings denoted the policy, so you expected inclusive use of the facilities as a price of your visit. Capture the emotion of the moment, when you see that bill, feel your heart race, and think to yourself, “Get me the manager!”

WW: Why has assigning appropriate status captured the attention of hospitals?

BF: Out of vigilance for penalties and fraud from recovery audit contractor (RAC) investigations, as well attentiveness to unnecessary readmissions, hospitals increasingly are categorizing patients under observation, rather than inpatient, status to avoid conflict with regulators. Beneficiaries are in the crosshairs because of this designation change, and much in the same way of our hotel charge, our patients experience sticker shock when they receive their bill. It is leading to confusion among providers and consternation within the Medicare recipient community.

WW: Why is there so much confusion around appropriate patient status?

BF: The dilemma stems from Medicare payment, and the key distinction between inpatient coverage (Part A) and outpatient coverage, including pharmaceuticals (Parts B and D). When a patient receives their discharge notification—without an “official” inpatient designation, sometimes staying greater than 24 to 48 hours in the ED or in a specially defined observation unit, beneficiary charges are different. This could result in discrete—and sometimes jolting—enrollee copayments and deductibles for drugs and services.

WW: I’ve heard observation status is having a big, adverse impact on patients who go to skilled nursing facilities. Why?

BF: If a patient requires a skilled nursing facility stay (the “three-day stay” inpatient requirement), Medicare will not pay because the patient never registered “official” hospital time. Patients and caregivers are not prepared for the unexpected bills, and consequently, tempers are rising. The rules for Medicare Advantage enrollees (Part C—commercial payers receive a fixed sum from CMS, and oversee parts A, B, and D for an individual beneficiary), which comprise 25% of the program, differ from conventional Medicare. However, commercial plans often shadow traditional, fee-for-service in their policies and, consequently, no exemplar of success in this realm exits.

 

 

WW: Why is the number of patients on observation status growing?

BF: Hospitals have significantly increased both the number of their observation stays, as well as their hourly lengths (>48 hours). Because the definition of “observation status” is vague, and even the one- to two-day window is inflating, hospitals and hospitalists often are navigating without a compass. Again, fear of fraud and penalty places hospitals and, indirectly, hospitalists—who often make judgments on admission grade—in a precarious position.

The responsibility of hospitals to notify beneficiaries of their status hinges on this murky determination milieu, which may change in real time during the stay, and makes for an unsatisfactory standard. Understandably, CMS is attempting to rectify this quandary, taking into account a hospital’s need to clarify its billing and designation practices, as well as the beneficiaries’ desire to obtain clear guidance on their responsibilities both during and after the stay. Hospitalists, of course, want direction on coding, along with an understanding of the impact their decisions will have on patients and subspecialty colleagues.

Let’s now bring in Dr. Conway, a pediatric hospitalist. I thank Dr. Flansbaum, who formulated the following questions.

BF/WW: Is it tenable to keep the current system in place? Would it help to require payors and providers to inform beneficiaries of inpatient versus observation status at time zero in a more rigorous, yet to-be-determined manner?

Dr. Conway: Current regulations only require CMS to inform beneficiaries when they are admitted as an inpatient and not when they are an outpatient receiving observation services. There are important implications for beneficiary coverage post-hospital stay, coverage of self-administered drugs, and beneficiary coinsurance from this distinction. As a hospitalist, I think it is best to inform the patient of their status, especially if it has the potential to impact beneficiary liability, including coverage of post-acute care. CMS prepared a pamphlet in 2009, “Are You a Hospital Inpatient or Outpatient? If You Have Medicare, Ask,” to educate beneficiaries on this issue. (Download a PDF of the pamphlet at www.medicare.gov/Publications/Pubs/pdf/11435.pdf.)

BF/WW: Due to the nature of how hospital care is changing, are admission decisions potentially becoming too conflicted an endeavor for inpatient caregivers?  

PC: We want admission decisions to be based on clinical considerations. The decision to admit a patient should be based on the clinical judgment of the primary-care, emergency medicine, and/or HM clinician.

BF/WW: Before the U.S. healthcare system matures to a more full-out, integrated model with internalized risk, can you envision any near-term code changes that might simplify the difficulties all parties are facing, in a budget-neutral fashion?

PC: CMS is currently investigating options to clarify when it is appropriate to admit the patient as an inpatient versus keeping the patient as an outpatient receiving observation services. We understand that this issue is of concern to hospitals, hospitalists, and patients, and we are considering carefully how to simplify the rules in a way that best meets the needs of patients and providers without increasing costs to the system.

With growing attention to observation status coming from patients and provider groups (the AMA is requesting that CMS revise its coverage rules), we will no doubt be hearing more about this going forward.

Dr. Whitcomb is medical director of healthcare quality at Baystate Medical Center in Springfield, Mass. He is a co-founder and past president of SHM. Email him at wfwhit@comcast.net.

Issue
The Hospitalist - 2012(07)
Publications
Topics
Sections

EDITOR’S NOTE: An incorrect version of Win Whitcomb’s “On the Horizon” column was published in the July issue of The Hospitalist. We deeply regret the error. The correct version of Dr. Whitcomb’s column appears this month, with proper attribution given to hospitalist Brad Flansbaum, DO, SFHM, who contributed to the column.

Assigning the appropriate status to patients (“inpatient” or “observation”) has emerged as a front-and-center issue for hospitalists. Also known as “medical necessity,” many HM groups have been called upon to help solve the “status” problem for their institutions. With nearly 1 in 5 hospitalized patients on observation status in U.S. hospitals, appropriately assigning status is now a dominant, system-level challenge for hospitalists.

This month, we asked two experts to shed light on the nature of this beast, with a focus on the impact on the patient. Brad Flansbaum, DO, SFHM, hospitalist at Lenox Hill Hospital in New York City, and Patrick Conway, MD, FAAP, MSC, SFHM, chief medical officer at the Centers for Medicare & Medicaid Services (CMS), were kind enough to participate in the interview. We start with Dr. Flansbaum.

Dr. Whitcomb: It appears that patients are caught in the middle of the observation status challenge, at least as it relates to footing the bill. Explain the patient perspective of being unwittingly placed on observation status.

Dr. Flansbaum: Recall your last credit card statement. On it is the hotel charge from your last out-of-town CME excursion. Below the total charge, which you were expecting, is a separate line item for a $75 “recreational fee.” You call the hotel, and they inform you that, because you used the hotel gym and pool—accessed with your room key, they levied the fee. No signs, alerts, or postings denoted the policy, so you expected inclusive use of the facilities as a price of your visit. Capture the emotion of the moment, when you see that bill, feel your heart race, and think to yourself, “Get me the manager!”

WW: Why has assigning appropriate status captured the attention of hospitals?

BF: Out of vigilance for penalties and fraud from recovery audit contractor (RAC) investigations, as well attentiveness to unnecessary readmissions, hospitals increasingly are categorizing patients under observation, rather than inpatient, status to avoid conflict with regulators. Beneficiaries are in the crosshairs because of this designation change, and much in the same way of our hotel charge, our patients experience sticker shock when they receive their bill. It is leading to confusion among providers and consternation within the Medicare recipient community.

WW: Why is there so much confusion around appropriate patient status?

BF: The dilemma stems from Medicare payment, and the key distinction between inpatient coverage (Part A) and outpatient coverage, including pharmaceuticals (Parts B and D). When a patient receives their discharge notification—without an “official” inpatient designation, sometimes staying greater than 24 to 48 hours in the ED or in a specially defined observation unit, beneficiary charges are different. This could result in discrete—and sometimes jolting—enrollee copayments and deductibles for drugs and services.

WW: I’ve heard observation status is having a big, adverse impact on patients who go to skilled nursing facilities. Why?

BF: If a patient requires a skilled nursing facility stay (the “three-day stay” inpatient requirement), Medicare will not pay because the patient never registered “official” hospital time. Patients and caregivers are not prepared for the unexpected bills, and consequently, tempers are rising. The rules for Medicare Advantage enrollees (Part C—commercial payers receive a fixed sum from CMS, and oversee parts A, B, and D for an individual beneficiary), which comprise 25% of the program, differ from conventional Medicare. However, commercial plans often shadow traditional, fee-for-service in their policies and, consequently, no exemplar of success in this realm exits.

 

 

WW: Why is the number of patients on observation status growing?

BF: Hospitals have significantly increased both the number of their observation stays, as well as their hourly lengths (>48 hours). Because the definition of “observation status” is vague, and even the one- to two-day window is inflating, hospitals and hospitalists often are navigating without a compass. Again, fear of fraud and penalty places hospitals and, indirectly, hospitalists—who often make judgments on admission grade—in a precarious position.

The responsibility of hospitals to notify beneficiaries of their status hinges on this murky determination milieu, which may change in real time during the stay, and makes for an unsatisfactory standard. Understandably, CMS is attempting to rectify this quandary, taking into account a hospital’s need to clarify its billing and designation practices, as well as the beneficiaries’ desire to obtain clear guidance on their responsibilities both during and after the stay. Hospitalists, of course, want direction on coding, along with an understanding of the impact their decisions will have on patients and subspecialty colleagues.

Let’s now bring in Dr. Conway, a pediatric hospitalist. I thank Dr. Flansbaum, who formulated the following questions.

BF/WW: Is it tenable to keep the current system in place? Would it help to require payors and providers to inform beneficiaries of inpatient versus observation status at time zero in a more rigorous, yet to-be-determined manner?

Dr. Conway: Current regulations only require CMS to inform beneficiaries when they are admitted as an inpatient and not when they are an outpatient receiving observation services. There are important implications for beneficiary coverage post-hospital stay, coverage of self-administered drugs, and beneficiary coinsurance from this distinction. As a hospitalist, I think it is best to inform the patient of their status, especially if it has the potential to impact beneficiary liability, including coverage of post-acute care. CMS prepared a pamphlet in 2009, “Are You a Hospital Inpatient or Outpatient? If You Have Medicare, Ask,” to educate beneficiaries on this issue. (Download a PDF of the pamphlet at www.medicare.gov/Publications/Pubs/pdf/11435.pdf.)

BF/WW: Due to the nature of how hospital care is changing, are admission decisions potentially becoming too conflicted an endeavor for inpatient caregivers?  

PC: We want admission decisions to be based on clinical considerations. The decision to admit a patient should be based on the clinical judgment of the primary-care, emergency medicine, and/or HM clinician.

BF/WW: Before the U.S. healthcare system matures to a more full-out, integrated model with internalized risk, can you envision any near-term code changes that might simplify the difficulties all parties are facing, in a budget-neutral fashion?

PC: CMS is currently investigating options to clarify when it is appropriate to admit the patient as an inpatient versus keeping the patient as an outpatient receiving observation services. We understand that this issue is of concern to hospitals, hospitalists, and patients, and we are considering carefully how to simplify the rules in a way that best meets the needs of patients and providers without increasing costs to the system.

With growing attention to observation status coming from patients and provider groups (the AMA is requesting that CMS revise its coverage rules), we will no doubt be hearing more about this going forward.

Dr. Whitcomb is medical director of healthcare quality at Baystate Medical Center in Springfield, Mass. He is a co-founder and past president of SHM. Email him at wfwhit@comcast.net.

EDITOR’S NOTE: An incorrect version of Win Whitcomb’s “On the Horizon” column was published in the July issue of The Hospitalist. We deeply regret the error. The correct version of Dr. Whitcomb’s column appears this month, with proper attribution given to hospitalist Brad Flansbaum, DO, SFHM, who contributed to the column.

Assigning the appropriate status to patients (“inpatient” or “observation”) has emerged as a front-and-center issue for hospitalists. Also known as “medical necessity,” many HM groups have been called upon to help solve the “status” problem for their institutions. With nearly 1 in 5 hospitalized patients on observation status in U.S. hospitals, appropriately assigning status is now a dominant, system-level challenge for hospitalists.

This month, we asked two experts to shed light on the nature of this beast, with a focus on the impact on the patient. Brad Flansbaum, DO, SFHM, hospitalist at Lenox Hill Hospital in New York City, and Patrick Conway, MD, FAAP, MSC, SFHM, chief medical officer at the Centers for Medicare & Medicaid Services (CMS), were kind enough to participate in the interview. We start with Dr. Flansbaum.

Dr. Whitcomb: It appears that patients are caught in the middle of the observation status challenge, at least as it relates to footing the bill. Explain the patient perspective of being unwittingly placed on observation status.

Dr. Flansbaum: Recall your last credit card statement. On it is the hotel charge from your last out-of-town CME excursion. Below the total charge, which you were expecting, is a separate line item for a $75 “recreational fee.” You call the hotel, and they inform you that, because you used the hotel gym and pool—accessed with your room key, they levied the fee. No signs, alerts, or postings denoted the policy, so you expected inclusive use of the facilities as a price of your visit. Capture the emotion of the moment, when you see that bill, feel your heart race, and think to yourself, “Get me the manager!”

WW: Why has assigning appropriate status captured the attention of hospitals?

BF: Out of vigilance for penalties and fraud from recovery audit contractor (RAC) investigations, as well attentiveness to unnecessary readmissions, hospitals increasingly are categorizing patients under observation, rather than inpatient, status to avoid conflict with regulators. Beneficiaries are in the crosshairs because of this designation change, and much in the same way of our hotel charge, our patients experience sticker shock when they receive their bill. It is leading to confusion among providers and consternation within the Medicare recipient community.

WW: Why is there so much confusion around appropriate patient status?

BF: The dilemma stems from Medicare payment, and the key distinction between inpatient coverage (Part A) and outpatient coverage, including pharmaceuticals (Parts B and D). When a patient receives their discharge notification—without an “official” inpatient designation, sometimes staying greater than 24 to 48 hours in the ED or in a specially defined observation unit, beneficiary charges are different. This could result in discrete—and sometimes jolting—enrollee copayments and deductibles for drugs and services.

WW: I’ve heard observation status is having a big, adverse impact on patients who go to skilled nursing facilities. Why?

BF: If a patient requires a skilled nursing facility stay (the “three-day stay” inpatient requirement), Medicare will not pay because the patient never registered “official” hospital time. Patients and caregivers are not prepared for the unexpected bills, and consequently, tempers are rising. The rules for Medicare Advantage enrollees (Part C—commercial payers receive a fixed sum from CMS, and oversee parts A, B, and D for an individual beneficiary), which comprise 25% of the program, differ from conventional Medicare. However, commercial plans often shadow traditional, fee-for-service in their policies and, consequently, no exemplar of success in this realm exits.

 

 

WW: Why is the number of patients on observation status growing?

BF: Hospitals have significantly increased both the number of their observation stays, as well as their hourly lengths (>48 hours). Because the definition of “observation status” is vague, and even the one- to two-day window is inflating, hospitals and hospitalists often are navigating without a compass. Again, fear of fraud and penalty places hospitals and, indirectly, hospitalists—who often make judgments on admission grade—in a precarious position.

The responsibility of hospitals to notify beneficiaries of their status hinges on this murky determination milieu, which may change in real time during the stay, and makes for an unsatisfactory standard. Understandably, CMS is attempting to rectify this quandary, taking into account a hospital’s need to clarify its billing and designation practices, as well as the beneficiaries’ desire to obtain clear guidance on their responsibilities both during and after the stay. Hospitalists, of course, want direction on coding, along with an understanding of the impact their decisions will have on patients and subspecialty colleagues.

Let’s now bring in Dr. Conway, a pediatric hospitalist. I thank Dr. Flansbaum, who formulated the following questions.

BF/WW: Is it tenable to keep the current system in place? Would it help to require payors and providers to inform beneficiaries of inpatient versus observation status at time zero in a more rigorous, yet to-be-determined manner?

Dr. Conway: Current regulations only require CMS to inform beneficiaries when they are admitted as an inpatient and not when they are an outpatient receiving observation services. There are important implications for beneficiary coverage post-hospital stay, coverage of self-administered drugs, and beneficiary coinsurance from this distinction. As a hospitalist, I think it is best to inform the patient of their status, especially if it has the potential to impact beneficiary liability, including coverage of post-acute care. CMS prepared a pamphlet in 2009, “Are You a Hospital Inpatient or Outpatient? If You Have Medicare, Ask,” to educate beneficiaries on this issue. (Download a PDF of the pamphlet at www.medicare.gov/Publications/Pubs/pdf/11435.pdf.)

BF/WW: Due to the nature of how hospital care is changing, are admission decisions potentially becoming too conflicted an endeavor for inpatient caregivers?  

PC: We want admission decisions to be based on clinical considerations. The decision to admit a patient should be based on the clinical judgment of the primary-care, emergency medicine, and/or HM clinician.

BF/WW: Before the U.S. healthcare system matures to a more full-out, integrated model with internalized risk, can you envision any near-term code changes that might simplify the difficulties all parties are facing, in a budget-neutral fashion?

PC: CMS is currently investigating options to clarify when it is appropriate to admit the patient as an inpatient versus keeping the patient as an outpatient receiving observation services. We understand that this issue is of concern to hospitals, hospitalists, and patients, and we are considering carefully how to simplify the rules in a way that best meets the needs of patients and providers without increasing costs to the system.

With growing attention to observation status coming from patients and provider groups (the AMA is requesting that CMS revise its coverage rules), we will no doubt be hearing more about this going forward.

Dr. Whitcomb is medical director of healthcare quality at Baystate Medical Center in Springfield, Mass. He is a co-founder and past president of SHM. Email him at wfwhit@comcast.net.

Issue
The Hospitalist - 2012(07)
Issue
The Hospitalist - 2012(07)
Publications
Publications
Topics
Article Type
Display Headline
Win Whitcomb: Spotlight on Medical Necessity
Display Headline
Win Whitcomb: Spotlight on Medical Necessity
Sections
Disallow All Ads
Content Gating
No Gating (article Unlocked/Free)

John Nelson: Admit Resolution

Article Type
Changed
Fri, 09/14/2018 - 12:22
Display Headline
John Nelson: Admit Resolution

John Nelson, MD, MHM

Editor’s note: Second in a two-part series.

I used last month’s column to frame the issue of disagreement between doctors over who should admit a particular patient, as well as discuss the value of good social connections to reduce the chance that divergent opinions lead to outright conflict. This month, I’ll review another worthwhile strategy—one that could be a definitive solution to these disagreements but often falls short of that goal in practice.

Service Agreements, or “Compacts,” between Physician Groups

If, at your hospital, there are reasonably frequent cases of divergent opinions regarding whether an ED admission or transfer from elsewhere should be admitted by a hospitalist or doctor in another specialty, why not meet in advance to decide this? Many hospitalist groups have held meetings with doctors in other specialties and now have a collection of agreements outlining scenarios, such as:

  • ESRD patients: Hospitalist admits for non-dialysis issues (pneumonia, diabetic issues, etc.); nephrologist admits for urgent dialysis issues (K+>6.3, pH<7.3, etc.).
  • Cardiology: Hospitalist admits CHF and non-ST elevation chest pain; cardiologist admits STEMI.
  • General surgery: Hospitalist admits ileus, pseudo obstruction, and SBO due to adhesions; general surgery admits bowel obstruction in “virgin abdomen,” volvulus, and any obstruction thought to require urgent surgery.

To be clear, I’m not suggesting the above guidelines are evidence-based or are the right ones for your institution. I just made these up, so yours might differ significantly. I just want to provide a sense of the kinds of issues these agreements typically cover. The comanagement section of the SHM website has several documents regarding hospitalist-orthopedic service agreements.

The Negotiation Process

It’s tempting for the lead hospitalist to just have a hallway chat with a spokesperson from the other specialty, then email a draft agreement, exchange a few messages until both parties are satisfied, then email a copy of the final document to all the doctors in both groups. This might work for some simple service agreements, but for any area with significant ambiguity or disagreements (or potential for disagreements), one or more in-person meetings are usually necessary. Ideally, several doctors in both groups will attend these meetings.

Much work could be done in advance of the first meeting, including surveying other practices to see how they decide which group admits the same kinds of patents, gathering any relevant published research, and possibly drafting a “straw man” proposed agreement. When meeting in person, the doctors will have a chance to explain their points of view, needs, and concerns, and gain a greater appreciation of the way “the other guy” sees things. An important purpose of the in-person meeting is to “look the other guy in the eye” to know if he or she really is committed to following through.

Remember that written agreements like these might become an issue in malpractice suits, so you might want to have them reviewed first by risk managers. You might also write them as guidelines rather than rigid protocols that don’t allow variations.

Maximize Effectiveness

Ideally, every doctor involved in the agreement should document their approval with a signature and date. My experience is that this doesn’t happen at most places, but if there is concern about whether everyone will comply, signing the document will probably help at least a little.

The completed agreements should be provided to all doctors in both groups, the ED, affected hospital nursing units, and others. Any new doctor should get a copy of all such agreements that might be relevant. And, most important, it should be made available electronically so that it is easy to find at any time. Some agreements cover uncommon events, and the doctors on duty might not remember what the agreement said and will need ready access to it.

 

 

Most service agreements should be reviewed and updated every two or three years or as needed. If there is confusion or controversy around a particular agreement, or if disagreements about which doctor does the admission are common despite the agreement, then an in-person meeting between the physician groups should be scheduled to revise or update it.

Keep Your Fingers Crossed

If it sounds like a lot of work to develop and maintain these agreements, it is. But they’re worth every bit of that work if they reduce confusion or discord. Sadly, for several reasons, they rarely prove so effective.

One doctor might think the agreement applies, but the other doctor says this patient is an exception and the agreement doesn’t apply. It is impossible to write an agreement that addresses all possible scenarios, so a doctor can argue that any particular patient falls outside the agreement because of things like comorbidities, which service admitted the patient last time (many agreements will have defined “bounce back” intervals), which primary-care physician (PCP) the patient sees, etc.

Even if there is no dispute about whether the agreement covers a particular patient, many doctors simply don’t feel obligated to uphold the agreement. Such a doctor might tell the ED doctor: “Yep, I signed the agreement, but only as a way to get the meeting over with. I was never in favor of it and just can’t admit the patient. Call the other guy to admit.” So in spite of all the work done to create a reasonable agreement, some doctors might feel entitled to ignore it when it suits them.

Compliance Is Critical

Sadly, my take is that despite the tremendous hoped-for benefits that service agreements might provide, poor compliance means they rarely achieve their potential. Even so, they are usually worth the time and effort to create them if it leads doctors in the two specialties to schedule time away from patient care to listen to the other group’s point of view and discuss how best to handle particular types of patients. In some cases, it will be the first time the two groups of doctors have set aside time to talk about the work they do together; that alone can have significant value.

Tom Lorence, MD, a Kaiser hospitalist in Portland, Ore., who is chief of hospital medicine for Northwest Permanente, developed more than 20 service agreements with many different specialties at his institution. He has found that they are worth the effort, and that they helped allay hospitalists’ feeling of being “dumped on.”

He also told me a rule that probably applies to all such agreements in any setting: The tie goes to the hospitalist—that is, when there is reasonable uncertainty or disagreement about which group should admit a patient, it is nearly always the hospitalist who will do so.

Dr. Nelson has been a practicing hospitalist since 1988. He is co-founder and past president of SHM, and principal in Nelson Flores Hospital Medicine Consultants. He is co-director for SHM’s “Best Practices in Managing a Hospital Medicine Program” course.

Issue
The Hospitalist - 2012(07)
Publications
Topics
Sections

John Nelson, MD, MHM

Editor’s note: Second in a two-part series.

I used last month’s column to frame the issue of disagreement between doctors over who should admit a particular patient, as well as discuss the value of good social connections to reduce the chance that divergent opinions lead to outright conflict. This month, I’ll review another worthwhile strategy—one that could be a definitive solution to these disagreements but often falls short of that goal in practice.

Service Agreements, or “Compacts,” between Physician Groups

If, at your hospital, there are reasonably frequent cases of divergent opinions regarding whether an ED admission or transfer from elsewhere should be admitted by a hospitalist or doctor in another specialty, why not meet in advance to decide this? Many hospitalist groups have held meetings with doctors in other specialties and now have a collection of agreements outlining scenarios, such as:

  • ESRD patients: Hospitalist admits for non-dialysis issues (pneumonia, diabetic issues, etc.); nephrologist admits for urgent dialysis issues (K+>6.3, pH<7.3, etc.).
  • Cardiology: Hospitalist admits CHF and non-ST elevation chest pain; cardiologist admits STEMI.
  • General surgery: Hospitalist admits ileus, pseudo obstruction, and SBO due to adhesions; general surgery admits bowel obstruction in “virgin abdomen,” volvulus, and any obstruction thought to require urgent surgery.

To be clear, I’m not suggesting the above guidelines are evidence-based or are the right ones for your institution. I just made these up, so yours might differ significantly. I just want to provide a sense of the kinds of issues these agreements typically cover. The comanagement section of the SHM website has several documents regarding hospitalist-orthopedic service agreements.

The Negotiation Process

It’s tempting for the lead hospitalist to just have a hallway chat with a spokesperson from the other specialty, then email a draft agreement, exchange a few messages until both parties are satisfied, then email a copy of the final document to all the doctors in both groups. This might work for some simple service agreements, but for any area with significant ambiguity or disagreements (or potential for disagreements), one or more in-person meetings are usually necessary. Ideally, several doctors in both groups will attend these meetings.

Much work could be done in advance of the first meeting, including surveying other practices to see how they decide which group admits the same kinds of patents, gathering any relevant published research, and possibly drafting a “straw man” proposed agreement. When meeting in person, the doctors will have a chance to explain their points of view, needs, and concerns, and gain a greater appreciation of the way “the other guy” sees things. An important purpose of the in-person meeting is to “look the other guy in the eye” to know if he or she really is committed to following through.

Remember that written agreements like these might become an issue in malpractice suits, so you might want to have them reviewed first by risk managers. You might also write them as guidelines rather than rigid protocols that don’t allow variations.

Maximize Effectiveness

Ideally, every doctor involved in the agreement should document their approval with a signature and date. My experience is that this doesn’t happen at most places, but if there is concern about whether everyone will comply, signing the document will probably help at least a little.

The completed agreements should be provided to all doctors in both groups, the ED, affected hospital nursing units, and others. Any new doctor should get a copy of all such agreements that might be relevant. And, most important, it should be made available electronically so that it is easy to find at any time. Some agreements cover uncommon events, and the doctors on duty might not remember what the agreement said and will need ready access to it.

 

 

Most service agreements should be reviewed and updated every two or three years or as needed. If there is confusion or controversy around a particular agreement, or if disagreements about which doctor does the admission are common despite the agreement, then an in-person meeting between the physician groups should be scheduled to revise or update it.

Keep Your Fingers Crossed

If it sounds like a lot of work to develop and maintain these agreements, it is. But they’re worth every bit of that work if they reduce confusion or discord. Sadly, for several reasons, they rarely prove so effective.

One doctor might think the agreement applies, but the other doctor says this patient is an exception and the agreement doesn’t apply. It is impossible to write an agreement that addresses all possible scenarios, so a doctor can argue that any particular patient falls outside the agreement because of things like comorbidities, which service admitted the patient last time (many agreements will have defined “bounce back” intervals), which primary-care physician (PCP) the patient sees, etc.

Even if there is no dispute about whether the agreement covers a particular patient, many doctors simply don’t feel obligated to uphold the agreement. Such a doctor might tell the ED doctor: “Yep, I signed the agreement, but only as a way to get the meeting over with. I was never in favor of it and just can’t admit the patient. Call the other guy to admit.” So in spite of all the work done to create a reasonable agreement, some doctors might feel entitled to ignore it when it suits them.

Compliance Is Critical

Sadly, my take is that despite the tremendous hoped-for benefits that service agreements might provide, poor compliance means they rarely achieve their potential. Even so, they are usually worth the time and effort to create them if it leads doctors in the two specialties to schedule time away from patient care to listen to the other group’s point of view and discuss how best to handle particular types of patients. In some cases, it will be the first time the two groups of doctors have set aside time to talk about the work they do together; that alone can have significant value.

Tom Lorence, MD, a Kaiser hospitalist in Portland, Ore., who is chief of hospital medicine for Northwest Permanente, developed more than 20 service agreements with many different specialties at his institution. He has found that they are worth the effort, and that they helped allay hospitalists’ feeling of being “dumped on.”

He also told me a rule that probably applies to all such agreements in any setting: The tie goes to the hospitalist—that is, when there is reasonable uncertainty or disagreement about which group should admit a patient, it is nearly always the hospitalist who will do so.

Dr. Nelson has been a practicing hospitalist since 1988. He is co-founder and past president of SHM, and principal in Nelson Flores Hospital Medicine Consultants. He is co-director for SHM’s “Best Practices in Managing a Hospital Medicine Program” course.

John Nelson, MD, MHM

Editor’s note: Second in a two-part series.

I used last month’s column to frame the issue of disagreement between doctors over who should admit a particular patient, as well as discuss the value of good social connections to reduce the chance that divergent opinions lead to outright conflict. This month, I’ll review another worthwhile strategy—one that could be a definitive solution to these disagreements but often falls short of that goal in practice.

Service Agreements, or “Compacts,” between Physician Groups

If, at your hospital, there are reasonably frequent cases of divergent opinions regarding whether an ED admission or transfer from elsewhere should be admitted by a hospitalist or doctor in another specialty, why not meet in advance to decide this? Many hospitalist groups have held meetings with doctors in other specialties and now have a collection of agreements outlining scenarios, such as:

  • ESRD patients: Hospitalist admits for non-dialysis issues (pneumonia, diabetic issues, etc.); nephrologist admits for urgent dialysis issues (K+>6.3, pH<7.3, etc.).
  • Cardiology: Hospitalist admits CHF and non-ST elevation chest pain; cardiologist admits STEMI.
  • General surgery: Hospitalist admits ileus, pseudo obstruction, and SBO due to adhesions; general surgery admits bowel obstruction in “virgin abdomen,” volvulus, and any obstruction thought to require urgent surgery.

To be clear, I’m not suggesting the above guidelines are evidence-based or are the right ones for your institution. I just made these up, so yours might differ significantly. I just want to provide a sense of the kinds of issues these agreements typically cover. The comanagement section of the SHM website has several documents regarding hospitalist-orthopedic service agreements.

The Negotiation Process

It’s tempting for the lead hospitalist to just have a hallway chat with a spokesperson from the other specialty, then email a draft agreement, exchange a few messages until both parties are satisfied, then email a copy of the final document to all the doctors in both groups. This might work for some simple service agreements, but for any area with significant ambiguity or disagreements (or potential for disagreements), one or more in-person meetings are usually necessary. Ideally, several doctors in both groups will attend these meetings.

Much work could be done in advance of the first meeting, including surveying other practices to see how they decide which group admits the same kinds of patents, gathering any relevant published research, and possibly drafting a “straw man” proposed agreement. When meeting in person, the doctors will have a chance to explain their points of view, needs, and concerns, and gain a greater appreciation of the way “the other guy” sees things. An important purpose of the in-person meeting is to “look the other guy in the eye” to know if he or she really is committed to following through.

Remember that written agreements like these might become an issue in malpractice suits, so you might want to have them reviewed first by risk managers. You might also write them as guidelines rather than rigid protocols that don’t allow variations.

Maximize Effectiveness

Ideally, every doctor involved in the agreement should document their approval with a signature and date. My experience is that this doesn’t happen at most places, but if there is concern about whether everyone will comply, signing the document will probably help at least a little.

The completed agreements should be provided to all doctors in both groups, the ED, affected hospital nursing units, and others. Any new doctor should get a copy of all such agreements that might be relevant. And, most important, it should be made available electronically so that it is easy to find at any time. Some agreements cover uncommon events, and the doctors on duty might not remember what the agreement said and will need ready access to it.

 

 

Most service agreements should be reviewed and updated every two or three years or as needed. If there is confusion or controversy around a particular agreement, or if disagreements about which doctor does the admission are common despite the agreement, then an in-person meeting between the physician groups should be scheduled to revise or update it.

Keep Your Fingers Crossed

If it sounds like a lot of work to develop and maintain these agreements, it is. But they’re worth every bit of that work if they reduce confusion or discord. Sadly, for several reasons, they rarely prove so effective.

One doctor might think the agreement applies, but the other doctor says this patient is an exception and the agreement doesn’t apply. It is impossible to write an agreement that addresses all possible scenarios, so a doctor can argue that any particular patient falls outside the agreement because of things like comorbidities, which service admitted the patient last time (many agreements will have defined “bounce back” intervals), which primary-care physician (PCP) the patient sees, etc.

Even if there is no dispute about whether the agreement covers a particular patient, many doctors simply don’t feel obligated to uphold the agreement. Such a doctor might tell the ED doctor: “Yep, I signed the agreement, but only as a way to get the meeting over with. I was never in favor of it and just can’t admit the patient. Call the other guy to admit.” So in spite of all the work done to create a reasonable agreement, some doctors might feel entitled to ignore it when it suits them.

Compliance Is Critical

Sadly, my take is that despite the tremendous hoped-for benefits that service agreements might provide, poor compliance means they rarely achieve their potential. Even so, they are usually worth the time and effort to create them if it leads doctors in the two specialties to schedule time away from patient care to listen to the other group’s point of view and discuss how best to handle particular types of patients. In some cases, it will be the first time the two groups of doctors have set aside time to talk about the work they do together; that alone can have significant value.

Tom Lorence, MD, a Kaiser hospitalist in Portland, Ore., who is chief of hospital medicine for Northwest Permanente, developed more than 20 service agreements with many different specialties at his institution. He has found that they are worth the effort, and that they helped allay hospitalists’ feeling of being “dumped on.”

He also told me a rule that probably applies to all such agreements in any setting: The tie goes to the hospitalist—that is, when there is reasonable uncertainty or disagreement about which group should admit a patient, it is nearly always the hospitalist who will do so.

Dr. Nelson has been a practicing hospitalist since 1988. He is co-founder and past president of SHM, and principal in Nelson Flores Hospital Medicine Consultants. He is co-director for SHM’s “Best Practices in Managing a Hospital Medicine Program” course.

Issue
The Hospitalist - 2012(07)
Issue
The Hospitalist - 2012(07)
Publications
Publications
Topics
Article Type
Display Headline
John Nelson: Admit Resolution
Display Headline
John Nelson: Admit Resolution
Sections
Disallow All Ads
Content Gating
No Gating (article Unlocked/Free)

Win Whitcomb: Staying ... and Paying

Article Type
Changed
Fri, 09/14/2018 - 12:22
Display Headline
Win Whitcomb: Staying ... and Paying

Take a minute to recall your last credit-card statement. On it, say, is the hotel charge from your last out-of-town CME excursion. Below the total charge you were expecting is a separate line-item charge of $75 for a “recreational fee.” Puzzled, you call the hotel. They inform you that because you used the gym and pool—accessed with your room key—they levied the fee. No signs, alerts, or postings to denote such a policy, you innocently expected inclusive use of the facilities in the price of your visit.

Capture the emotion of that moment. It is likely your heart will race and you will think to yourself, “Get me the manager!”

Out of vigilance for penalties and fraud from recovery audit contractor (RAC) investigations, as well attentiveness to unnecessary readmissions, hospitals increasingly are categorizing Medicare patients under observation, rather than inpatient, status. This is to avoid conflict with regulators. Beneficiaries are in the crosshairs because of this designation change and, much in the same way as with our hotel charge, they also experience sticker shock when they get their bills. It is leading to confusion among providers, and consternation within the Medicare recipient community.

Why is this occurring? The dilemma stems from Medicare payments and the key distinction between inpatient coverage (Part A) and outpatient coverage (Parts B and D). When a patient receives their discharge notification—without an “official” inpatient designation—sometimes staying greater than 24 to 48 hours in the ED or in a specially defined observation unit can mean that beneficiary charges are different. This could result in discrete and sometimes jolting copayments and deductibles for drugs and services.

Worse, if beneficiaries require a skilled nursing facility stay (the “three-day stay” inpatient requirement), Medicare will not pay because they never registered “official” hospital time. Patients and caregivers are not prepared for the unexpected bills, and, consequently, tempers are rising.

The rules for Medicare Advantage enrollees, who make up 25% of the program, differ from conventional Medicare. However, commercial plans often shadow traditional fee-for-service in their policies, and, consequently, no exemplar of success in this realm exits.

Hospitals have increased both the number of their observation stays, as well as their hourly lengths (>48 hours). Because the definition of “observation status” is vague, and even the one- to two-day window is inflating, hospitals and hospitalists are often left to navigate without a compass. Again, fear of fraud and penalties places hospitals—and, indirectly, hospitalists, who often make judgments on admission grade—in a precarious position.

The responsibility of hospitals to notify beneficiaries of their status hinges on this murky determination milieu, which might change in real time during the stay and makes for an unsatisfactory standard. Understandably, CMS is attempting to rectify this quandary, taking into account a hospital’s need to clarify its billing and designation practices as well as beneficiaries’ desire to obtain clear guidance on their responsibilities both during and after a stay.

Hospitalists, of course, want direction on coding and an understanding of the impact their decisions will have on patients and subspecialty colleagues. To that end, Patrick Conway, MD, SFHM, chief medical officer for the Centers for Medicare & Medicaid (CMS), offers some enlightenment on this matter:

Q: Is it tenable to keep the current system in place? However, as a fix, require payors and providers to inform beneficiaries of inpatient versus observation status at time zero in a more rigorous, yet-to-be determined manner?

A: Current regulations only require CMS to inform beneficiaries when they are admitted as an inpatient and not when they are an outpatient receiving observation services. There are important implications for coverage for beneficiaries post-hospital stay, coverage of self-administered drugs, and beneficiary coinsurance from this distinction. As a hospitalist, I think it is best to inform the patient of their status, especially if it has the potential to impact beneficiary liability, including coverage of post-acute care. CMS prepared a pamphlet in 2009, “Are You a Hospital Inpatient or Outpatient? If You Have Medicare, Ask!” to educate beneficiaries on this issue. The pamphlet can found at http://www.medicare.gov/Publications/Pubs/pdf/11435.pdf.

 

 

Q: Due to the nature of how hospital care is changing, are admission decisions potentially becoming too conflicted an endeavor for inpatient caregivers?

A: We want admission decisions to be based on clinical considerations. The decision to admit a patient should be based on the clinical judgment of the primary care, emergency medicine, and/or hospital medicine clinician.

Q: Before the U.S. healthcare system matures to a more integrated model with internalized risk, can you envision any near-term code changes that might simplify the difficulties all parties are facing, in a budget-neutral fashion?

A: CMS is currently investigating options to clarify when it is appropriate to admit the patient as an inpatient versus keeping the patient as an outpatient receiving observation services. We understand that this issue is of concern to hospitals, hospitalists, and patients, and we are considering carefully how to simplify the rules in a way that best meets the needs of patients and providers without increasing costs to the system.

I expect we will hear more from Medicare in the near-term on this matter. Stay tuned.

For more about the patient’s perspective on this issue, please see Brad’s blog: www.hospitalmedicine.org/pmblog.

Dr. Whitcomb is medical director of healthcare quality at Baystate Medical Center in Springfield, Mass. He is a co-founder and past president of SHM. Email him at wfwhit@comcast.net.

Issue
The Hospitalist - 2012(07)
Publications
Topics
Sections

Take a minute to recall your last credit-card statement. On it, say, is the hotel charge from your last out-of-town CME excursion. Below the total charge you were expecting is a separate line-item charge of $75 for a “recreational fee.” Puzzled, you call the hotel. They inform you that because you used the gym and pool—accessed with your room key—they levied the fee. No signs, alerts, or postings to denote such a policy, you innocently expected inclusive use of the facilities in the price of your visit.

Capture the emotion of that moment. It is likely your heart will race and you will think to yourself, “Get me the manager!”

Out of vigilance for penalties and fraud from recovery audit contractor (RAC) investigations, as well attentiveness to unnecessary readmissions, hospitals increasingly are categorizing Medicare patients under observation, rather than inpatient, status. This is to avoid conflict with regulators. Beneficiaries are in the crosshairs because of this designation change and, much in the same way as with our hotel charge, they also experience sticker shock when they get their bills. It is leading to confusion among providers, and consternation within the Medicare recipient community.

Why is this occurring? The dilemma stems from Medicare payments and the key distinction between inpatient coverage (Part A) and outpatient coverage (Parts B and D). When a patient receives their discharge notification—without an “official” inpatient designation—sometimes staying greater than 24 to 48 hours in the ED or in a specially defined observation unit can mean that beneficiary charges are different. This could result in discrete and sometimes jolting copayments and deductibles for drugs and services.

Worse, if beneficiaries require a skilled nursing facility stay (the “three-day stay” inpatient requirement), Medicare will not pay because they never registered “official” hospital time. Patients and caregivers are not prepared for the unexpected bills, and, consequently, tempers are rising.

The rules for Medicare Advantage enrollees, who make up 25% of the program, differ from conventional Medicare. However, commercial plans often shadow traditional fee-for-service in their policies, and, consequently, no exemplar of success in this realm exits.

Hospitals have increased both the number of their observation stays, as well as their hourly lengths (>48 hours). Because the definition of “observation status” is vague, and even the one- to two-day window is inflating, hospitals and hospitalists are often left to navigate without a compass. Again, fear of fraud and penalties places hospitals—and, indirectly, hospitalists, who often make judgments on admission grade—in a precarious position.

The responsibility of hospitals to notify beneficiaries of their status hinges on this murky determination milieu, which might change in real time during the stay and makes for an unsatisfactory standard. Understandably, CMS is attempting to rectify this quandary, taking into account a hospital’s need to clarify its billing and designation practices as well as beneficiaries’ desire to obtain clear guidance on their responsibilities both during and after a stay.

Hospitalists, of course, want direction on coding and an understanding of the impact their decisions will have on patients and subspecialty colleagues. To that end, Patrick Conway, MD, SFHM, chief medical officer for the Centers for Medicare & Medicaid (CMS), offers some enlightenment on this matter:

Q: Is it tenable to keep the current system in place? However, as a fix, require payors and providers to inform beneficiaries of inpatient versus observation status at time zero in a more rigorous, yet-to-be determined manner?

A: Current regulations only require CMS to inform beneficiaries when they are admitted as an inpatient and not when they are an outpatient receiving observation services. There are important implications for coverage for beneficiaries post-hospital stay, coverage of self-administered drugs, and beneficiary coinsurance from this distinction. As a hospitalist, I think it is best to inform the patient of their status, especially if it has the potential to impact beneficiary liability, including coverage of post-acute care. CMS prepared a pamphlet in 2009, “Are You a Hospital Inpatient or Outpatient? If You Have Medicare, Ask!” to educate beneficiaries on this issue. The pamphlet can found at http://www.medicare.gov/Publications/Pubs/pdf/11435.pdf.

 

 

Q: Due to the nature of how hospital care is changing, are admission decisions potentially becoming too conflicted an endeavor for inpatient caregivers?

A: We want admission decisions to be based on clinical considerations. The decision to admit a patient should be based on the clinical judgment of the primary care, emergency medicine, and/or hospital medicine clinician.

Q: Before the U.S. healthcare system matures to a more integrated model with internalized risk, can you envision any near-term code changes that might simplify the difficulties all parties are facing, in a budget-neutral fashion?

A: CMS is currently investigating options to clarify when it is appropriate to admit the patient as an inpatient versus keeping the patient as an outpatient receiving observation services. We understand that this issue is of concern to hospitals, hospitalists, and patients, and we are considering carefully how to simplify the rules in a way that best meets the needs of patients and providers without increasing costs to the system.

I expect we will hear more from Medicare in the near-term on this matter. Stay tuned.

For more about the patient’s perspective on this issue, please see Brad’s blog: www.hospitalmedicine.org/pmblog.

Dr. Whitcomb is medical director of healthcare quality at Baystate Medical Center in Springfield, Mass. He is a co-founder and past president of SHM. Email him at wfwhit@comcast.net.

Take a minute to recall your last credit-card statement. On it, say, is the hotel charge from your last out-of-town CME excursion. Below the total charge you were expecting is a separate line-item charge of $75 for a “recreational fee.” Puzzled, you call the hotel. They inform you that because you used the gym and pool—accessed with your room key—they levied the fee. No signs, alerts, or postings to denote such a policy, you innocently expected inclusive use of the facilities in the price of your visit.

Capture the emotion of that moment. It is likely your heart will race and you will think to yourself, “Get me the manager!”

Out of vigilance for penalties and fraud from recovery audit contractor (RAC) investigations, as well attentiveness to unnecessary readmissions, hospitals increasingly are categorizing Medicare patients under observation, rather than inpatient, status. This is to avoid conflict with regulators. Beneficiaries are in the crosshairs because of this designation change and, much in the same way as with our hotel charge, they also experience sticker shock when they get their bills. It is leading to confusion among providers, and consternation within the Medicare recipient community.

Why is this occurring? The dilemma stems from Medicare payments and the key distinction between inpatient coverage (Part A) and outpatient coverage (Parts B and D). When a patient receives their discharge notification—without an “official” inpatient designation—sometimes staying greater than 24 to 48 hours in the ED or in a specially defined observation unit can mean that beneficiary charges are different. This could result in discrete and sometimes jolting copayments and deductibles for drugs and services.

Worse, if beneficiaries require a skilled nursing facility stay (the “three-day stay” inpatient requirement), Medicare will not pay because they never registered “official” hospital time. Patients and caregivers are not prepared for the unexpected bills, and, consequently, tempers are rising.

The rules for Medicare Advantage enrollees, who make up 25% of the program, differ from conventional Medicare. However, commercial plans often shadow traditional fee-for-service in their policies, and, consequently, no exemplar of success in this realm exits.

Hospitals have increased both the number of their observation stays, as well as their hourly lengths (>48 hours). Because the definition of “observation status” is vague, and even the one- to two-day window is inflating, hospitals and hospitalists are often left to navigate without a compass. Again, fear of fraud and penalties places hospitals—and, indirectly, hospitalists, who often make judgments on admission grade—in a precarious position.

The responsibility of hospitals to notify beneficiaries of their status hinges on this murky determination milieu, which might change in real time during the stay and makes for an unsatisfactory standard. Understandably, CMS is attempting to rectify this quandary, taking into account a hospital’s need to clarify its billing and designation practices as well as beneficiaries’ desire to obtain clear guidance on their responsibilities both during and after a stay.

Hospitalists, of course, want direction on coding and an understanding of the impact their decisions will have on patients and subspecialty colleagues. To that end, Patrick Conway, MD, SFHM, chief medical officer for the Centers for Medicare & Medicaid (CMS), offers some enlightenment on this matter:

Q: Is it tenable to keep the current system in place? However, as a fix, require payors and providers to inform beneficiaries of inpatient versus observation status at time zero in a more rigorous, yet-to-be determined manner?

A: Current regulations only require CMS to inform beneficiaries when they are admitted as an inpatient and not when they are an outpatient receiving observation services. There are important implications for coverage for beneficiaries post-hospital stay, coverage of self-administered drugs, and beneficiary coinsurance from this distinction. As a hospitalist, I think it is best to inform the patient of their status, especially if it has the potential to impact beneficiary liability, including coverage of post-acute care. CMS prepared a pamphlet in 2009, “Are You a Hospital Inpatient or Outpatient? If You Have Medicare, Ask!” to educate beneficiaries on this issue. The pamphlet can found at http://www.medicare.gov/Publications/Pubs/pdf/11435.pdf.

 

 

Q: Due to the nature of how hospital care is changing, are admission decisions potentially becoming too conflicted an endeavor for inpatient caregivers?

A: We want admission decisions to be based on clinical considerations. The decision to admit a patient should be based on the clinical judgment of the primary care, emergency medicine, and/or hospital medicine clinician.

Q: Before the U.S. healthcare system matures to a more integrated model with internalized risk, can you envision any near-term code changes that might simplify the difficulties all parties are facing, in a budget-neutral fashion?

A: CMS is currently investigating options to clarify when it is appropriate to admit the patient as an inpatient versus keeping the patient as an outpatient receiving observation services. We understand that this issue is of concern to hospitals, hospitalists, and patients, and we are considering carefully how to simplify the rules in a way that best meets the needs of patients and providers without increasing costs to the system.

I expect we will hear more from Medicare in the near-term on this matter. Stay tuned.

For more about the patient’s perspective on this issue, please see Brad’s blog: www.hospitalmedicine.org/pmblog.

Dr. Whitcomb is medical director of healthcare quality at Baystate Medical Center in Springfield, Mass. He is a co-founder and past president of SHM. Email him at wfwhit@comcast.net.

Issue
The Hospitalist - 2012(07)
Issue
The Hospitalist - 2012(07)
Publications
Publications
Topics
Article Type
Display Headline
Win Whitcomb: Staying ... and Paying
Display Headline
Win Whitcomb: Staying ... and Paying
Sections
Disallow All Ads
Content Gating
No Gating (article Unlocked/Free)

Does long-acting reversible contraception prevent unintended pregnancy better than OCs, transdermal patch, and vaginal ring— regardless of a patient’s age?

Article Type
Changed
Tue, 08/28/2018 - 10:59
Display Headline
Does long-acting reversible contraception prevent unintended pregnancy better than OCs, transdermal patch, and vaginal ring— regardless of a patient’s age?

TELL US…

Do you currently offer, or do you plan to begin offering, long-acting reversible contraceptives as first-line birth control options to your patients?

We want to hear from you! Tell us what you think.

Because half of US pregnancies continue to be unintended, rates of induced abortion in our patients remain high. In addition, unintended pregnancies lead to negative health and social consequences for women and infants. This recent report from the Contraceptive Choice Project, spearheaded by Dr. Jeffrey Peipert from the Department of Obstetrics and Gynecology, Washington University School of Medicine, St. Louis, Missouri, and published in New England Journal of Medicine underscores the high efficacy of long-acting reversible contraceptives, a term referring to IUDs and the contraceptive implant, in preventing unintended pregnancy in a US population.

Details of the study

Eligibility in the Project included age 14 to 45 years, residence in the St. Louis, Missouri, area, and the need for contraception. The woman’s contraceptive of choice was made available at no charge, with most women choosing a long-acting method. The published study includes outcomes for 7,486 women who used OCs, the patch, the ring, an IUD, implant, or depot medroxyprogesterone acetate (DMPA) injections.

Among women using OCs, the patch, or the ring, the pregnancy rate was 4.55 per 100 participant-years. This rate was nearly 22-fold higher than that observed in women using IUDs or the implant (hazard ratio, 21.8; 95% confidence interval, 13.7–34.9): that rate was 0.27 per 100 participant-years. A similar low rate of pregnancy was noted among women who chose DMPA and returned every 3 months for follow-up injections.

Among women younger than 21 years who used OCs, the patch, or the ring, the rate of unintended pregnancy was twice as high as in older women using these same methods. By contrast, regardless of age, pregnancy rates were uniformly low among women using long-acting methods.

Study limitations

The authors point out that their study design was not randomized—participants were at high risk for unintended pregnancy and willing to begin using a new contraceptive method, which could have resulted in higher adherence rates and lower failure rates.

Access is ongoing barrier to use

These important data from the Contraceptive Choice Project clarify that long-acting reversible contraceptives represent powerful tools to help women minimize unintended pregnancy and induced abortion, and that women will choose these methods if they are accessible.

The findings in this report also make it clear that rates of unintended pregnancy are particularly high among adolescents using shorter-acting hormonal contraceptives (OCs, patch, or ring) and that longer-acting contraceptives are particularly useful in our younger patients. Other recent reports have provided clear evidence that immediately providing long-acting contraceptives after childbirth or induced abortion reduces unintended pregnancy in these settings.1,2

In the United States, inadequate access to long-acting reversible contraceptives continues to constrain use. Accordingly, insurance policies that fully cover longer-acting contraceptives could go a long way toward reducing the rate of unintended pregnancies and induced abortions in our patients.

If long-acting reversible contraceptives become more available in the United States, I look forward to a time when the great majority of our patients’ pregnancies are planned and when far fewer women will face the troubling prospect of an induced abortion.

WHAT THIS EVIDENCE MEANS FOR PRACTICE

Given the limitations of shorter-acting methods, it is time to change our paradigm with regard to counseling women seeking contraception. Longer-acting contraceptives, including IUDs, the implant and injections, should be regarded as first-line options. Shorter-acting methods, including OCs, the patch, and the ring, should be considered second-line options and provided to women who choose not to use longer-acting methods or those who financially do not have access to them.

ANDREW M. KAUNITZ, MD

We want to hear from you! Tell us what you think.

References

1. Tocce KM, Sheeder JL, Teal SB. Rapid repeat pregnancy in adolescents: do immediate postpartum contraceptive implants make a difference? Am J Obstet Gynecol. 2012;206(6):481. e1-e7.

2. Bednarek PH, Creinin MD, Reeves MF, Cwiak C, Espey E, Jensen JT. Post-Aspiration IUD Randomization (PAIR) Study Trial Group. Immediate versus delayed IUD insertion after uterine aspiration. N Engl J Med. 20119;364(23):2208-2217.

Article PDF
Author and Disclosure Information

Yes. In this prospective cohort study of 7,486 women, 156 unintended pregnancies were attributed to contraception failure. Failure rates at years 1, 2, and 3 in oral contraceptive (OC), patch, or ring users were 4.8%, 7.8%, and 9.4%, respectively, compared with 0.3%, 0.6%, and 0.9% in intrauterine device (IUD) or implant users (P<.001). For OC, patch, or ring users, those younger than age 21 had almost twice the risk of a pregnancy as older study participants (hazard ratio, 1.9; 95% confidence interval, 1.2–2.8). No significant difference was found in the pregnancy rate according to age in women using IUDs or implants.

Winner B, Peipert JF, Zhao O, et al. Effectiveness of long-acting reversible contraception. N Engl J Med. 2012;366(21):1998–2007.

EXPERT COMMENTARY

Andrew M. Kaunitz, MD
Professor and Associate Chairman, Department of Obstetrics and Gynecology, University of Florida College of Medicine-Jacksonville. He serves on the OBG Management Board of Editors.

Issue
OBG Management - 24(07)
Publications
Topics
Page Number
18-22
Legacy Keywords
Andrew M. Kaunitz MD;long-acting reversible contraception;LARC;unintended pregnancy;OCs;first-line options;oral contraceptives;contraception failure;unintended pregnancy;itrauterine device;IUD;transdermal patch;vaginal ring;contraceptive implant;depot medroxyprogesterone acetate injections;DMPA;change our paradigm;shorter-acting methods;second-line options;planned pregnancy;inadequate access;induced abortion;
Sections
Author and Disclosure Information

Yes. In this prospective cohort study of 7,486 women, 156 unintended pregnancies were attributed to contraception failure. Failure rates at years 1, 2, and 3 in oral contraceptive (OC), patch, or ring users were 4.8%, 7.8%, and 9.4%, respectively, compared with 0.3%, 0.6%, and 0.9% in intrauterine device (IUD) or implant users (P<.001). For OC, patch, or ring users, those younger than age 21 had almost twice the risk of a pregnancy as older study participants (hazard ratio, 1.9; 95% confidence interval, 1.2–2.8). No significant difference was found in the pregnancy rate according to age in women using IUDs or implants.

Winner B, Peipert JF, Zhao O, et al. Effectiveness of long-acting reversible contraception. N Engl J Med. 2012;366(21):1998–2007.

EXPERT COMMENTARY

Andrew M. Kaunitz, MD
Professor and Associate Chairman, Department of Obstetrics and Gynecology, University of Florida College of Medicine-Jacksonville. He serves on the OBG Management Board of Editors.

Author and Disclosure Information

Yes. In this prospective cohort study of 7,486 women, 156 unintended pregnancies were attributed to contraception failure. Failure rates at years 1, 2, and 3 in oral contraceptive (OC), patch, or ring users were 4.8%, 7.8%, and 9.4%, respectively, compared with 0.3%, 0.6%, and 0.9% in intrauterine device (IUD) or implant users (P<.001). For OC, patch, or ring users, those younger than age 21 had almost twice the risk of a pregnancy as older study participants (hazard ratio, 1.9; 95% confidence interval, 1.2–2.8). No significant difference was found in the pregnancy rate according to age in women using IUDs or implants.

Winner B, Peipert JF, Zhao O, et al. Effectiveness of long-acting reversible contraception. N Engl J Med. 2012;366(21):1998–2007.

EXPERT COMMENTARY

Andrew M. Kaunitz, MD
Professor and Associate Chairman, Department of Obstetrics and Gynecology, University of Florida College of Medicine-Jacksonville. He serves on the OBG Management Board of Editors.

Article PDF
Article PDF

TELL US…

Do you currently offer, or do you plan to begin offering, long-acting reversible contraceptives as first-line birth control options to your patients?

We want to hear from you! Tell us what you think.

Because half of US pregnancies continue to be unintended, rates of induced abortion in our patients remain high. In addition, unintended pregnancies lead to negative health and social consequences for women and infants. This recent report from the Contraceptive Choice Project, spearheaded by Dr. Jeffrey Peipert from the Department of Obstetrics and Gynecology, Washington University School of Medicine, St. Louis, Missouri, and published in New England Journal of Medicine underscores the high efficacy of long-acting reversible contraceptives, a term referring to IUDs and the contraceptive implant, in preventing unintended pregnancy in a US population.

Details of the study

Eligibility in the Project included age 14 to 45 years, residence in the St. Louis, Missouri, area, and the need for contraception. The woman’s contraceptive of choice was made available at no charge, with most women choosing a long-acting method. The published study includes outcomes for 7,486 women who used OCs, the patch, the ring, an IUD, implant, or depot medroxyprogesterone acetate (DMPA) injections.

Among women using OCs, the patch, or the ring, the pregnancy rate was 4.55 per 100 participant-years. This rate was nearly 22-fold higher than that observed in women using IUDs or the implant (hazard ratio, 21.8; 95% confidence interval, 13.7–34.9): that rate was 0.27 per 100 participant-years. A similar low rate of pregnancy was noted among women who chose DMPA and returned every 3 months for follow-up injections.

Among women younger than 21 years who used OCs, the patch, or the ring, the rate of unintended pregnancy was twice as high as in older women using these same methods. By contrast, regardless of age, pregnancy rates were uniformly low among women using long-acting methods.

Study limitations

The authors point out that their study design was not randomized—participants were at high risk for unintended pregnancy and willing to begin using a new contraceptive method, which could have resulted in higher adherence rates and lower failure rates.

Access is ongoing barrier to use

These important data from the Contraceptive Choice Project clarify that long-acting reversible contraceptives represent powerful tools to help women minimize unintended pregnancy and induced abortion, and that women will choose these methods if they are accessible.

The findings in this report also make it clear that rates of unintended pregnancy are particularly high among adolescents using shorter-acting hormonal contraceptives (OCs, patch, or ring) and that longer-acting contraceptives are particularly useful in our younger patients. Other recent reports have provided clear evidence that immediately providing long-acting contraceptives after childbirth or induced abortion reduces unintended pregnancy in these settings.1,2

In the United States, inadequate access to long-acting reversible contraceptives continues to constrain use. Accordingly, insurance policies that fully cover longer-acting contraceptives could go a long way toward reducing the rate of unintended pregnancies and induced abortions in our patients.

If long-acting reversible contraceptives become more available in the United States, I look forward to a time when the great majority of our patients’ pregnancies are planned and when far fewer women will face the troubling prospect of an induced abortion.

WHAT THIS EVIDENCE MEANS FOR PRACTICE

Given the limitations of shorter-acting methods, it is time to change our paradigm with regard to counseling women seeking contraception. Longer-acting contraceptives, including IUDs, the implant and injections, should be regarded as first-line options. Shorter-acting methods, including OCs, the patch, and the ring, should be considered second-line options and provided to women who choose not to use longer-acting methods or those who financially do not have access to them.

ANDREW M. KAUNITZ, MD

We want to hear from you! Tell us what you think.

TELL US…

Do you currently offer, or do you plan to begin offering, long-acting reversible contraceptives as first-line birth control options to your patients?

We want to hear from you! Tell us what you think.

Because half of US pregnancies continue to be unintended, rates of induced abortion in our patients remain high. In addition, unintended pregnancies lead to negative health and social consequences for women and infants. This recent report from the Contraceptive Choice Project, spearheaded by Dr. Jeffrey Peipert from the Department of Obstetrics and Gynecology, Washington University School of Medicine, St. Louis, Missouri, and published in New England Journal of Medicine underscores the high efficacy of long-acting reversible contraceptives, a term referring to IUDs and the contraceptive implant, in preventing unintended pregnancy in a US population.

Details of the study

Eligibility in the Project included age 14 to 45 years, residence in the St. Louis, Missouri, area, and the need for contraception. The woman’s contraceptive of choice was made available at no charge, with most women choosing a long-acting method. The published study includes outcomes for 7,486 women who used OCs, the patch, the ring, an IUD, implant, or depot medroxyprogesterone acetate (DMPA) injections.

Among women using OCs, the patch, or the ring, the pregnancy rate was 4.55 per 100 participant-years. This rate was nearly 22-fold higher than that observed in women using IUDs or the implant (hazard ratio, 21.8; 95% confidence interval, 13.7–34.9): that rate was 0.27 per 100 participant-years. A similar low rate of pregnancy was noted among women who chose DMPA and returned every 3 months for follow-up injections.

Among women younger than 21 years who used OCs, the patch, or the ring, the rate of unintended pregnancy was twice as high as in older women using these same methods. By contrast, regardless of age, pregnancy rates were uniformly low among women using long-acting methods.

Study limitations

The authors point out that their study design was not randomized—participants were at high risk for unintended pregnancy and willing to begin using a new contraceptive method, which could have resulted in higher adherence rates and lower failure rates.

Access is ongoing barrier to use

These important data from the Contraceptive Choice Project clarify that long-acting reversible contraceptives represent powerful tools to help women minimize unintended pregnancy and induced abortion, and that women will choose these methods if they are accessible.

The findings in this report also make it clear that rates of unintended pregnancy are particularly high among adolescents using shorter-acting hormonal contraceptives (OCs, patch, or ring) and that longer-acting contraceptives are particularly useful in our younger patients. Other recent reports have provided clear evidence that immediately providing long-acting contraceptives after childbirth or induced abortion reduces unintended pregnancy in these settings.1,2

In the United States, inadequate access to long-acting reversible contraceptives continues to constrain use. Accordingly, insurance policies that fully cover longer-acting contraceptives could go a long way toward reducing the rate of unintended pregnancies and induced abortions in our patients.

If long-acting reversible contraceptives become more available in the United States, I look forward to a time when the great majority of our patients’ pregnancies are planned and when far fewer women will face the troubling prospect of an induced abortion.

WHAT THIS EVIDENCE MEANS FOR PRACTICE

Given the limitations of shorter-acting methods, it is time to change our paradigm with regard to counseling women seeking contraception. Longer-acting contraceptives, including IUDs, the implant and injections, should be regarded as first-line options. Shorter-acting methods, including OCs, the patch, and the ring, should be considered second-line options and provided to women who choose not to use longer-acting methods or those who financially do not have access to them.

ANDREW M. KAUNITZ, MD

We want to hear from you! Tell us what you think.

References

1. Tocce KM, Sheeder JL, Teal SB. Rapid repeat pregnancy in adolescents: do immediate postpartum contraceptive implants make a difference? Am J Obstet Gynecol. 2012;206(6):481. e1-e7.

2. Bednarek PH, Creinin MD, Reeves MF, Cwiak C, Espey E, Jensen JT. Post-Aspiration IUD Randomization (PAIR) Study Trial Group. Immediate versus delayed IUD insertion after uterine aspiration. N Engl J Med. 20119;364(23):2208-2217.

References

1. Tocce KM, Sheeder JL, Teal SB. Rapid repeat pregnancy in adolescents: do immediate postpartum contraceptive implants make a difference? Am J Obstet Gynecol. 2012;206(6):481. e1-e7.

2. Bednarek PH, Creinin MD, Reeves MF, Cwiak C, Espey E, Jensen JT. Post-Aspiration IUD Randomization (PAIR) Study Trial Group. Immediate versus delayed IUD insertion after uterine aspiration. N Engl J Med. 20119;364(23):2208-2217.

Issue
OBG Management - 24(07)
Issue
OBG Management - 24(07)
Page Number
18-22
Page Number
18-22
Publications
Publications
Topics
Article Type
Display Headline
Does long-acting reversible contraception prevent unintended pregnancy better than OCs, transdermal patch, and vaginal ring— regardless of a patient’s age?
Display Headline
Does long-acting reversible contraception prevent unintended pregnancy better than OCs, transdermal patch, and vaginal ring— regardless of a patient’s age?
Legacy Keywords
Andrew M. Kaunitz MD;long-acting reversible contraception;LARC;unintended pregnancy;OCs;first-line options;oral contraceptives;contraception failure;unintended pregnancy;itrauterine device;IUD;transdermal patch;vaginal ring;contraceptive implant;depot medroxyprogesterone acetate injections;DMPA;change our paradigm;shorter-acting methods;second-line options;planned pregnancy;inadequate access;induced abortion;
Legacy Keywords
Andrew M. Kaunitz MD;long-acting reversible contraception;LARC;unintended pregnancy;OCs;first-line options;oral contraceptives;contraception failure;unintended pregnancy;itrauterine device;IUD;transdermal patch;vaginal ring;contraceptive implant;depot medroxyprogesterone acetate injections;DMPA;change our paradigm;shorter-acting methods;second-line options;planned pregnancy;inadequate access;induced abortion;
Sections
Article Source

PURLs Copyright

Inside the Article

Article PDF Media